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Abstract  
NK cells are emerging as potent regulators of adaptive immunity in virus infection. 
Our group recently documented the partially TRAIL-dependent deletion of 
HBV-specific T cells by NK cells. For this study, we investigated the underlying 
interactions between NK cells and T cells through the NKG2D pathway in chronic 
HBV infection.  
In this study, we observed that activated and HBV-specific T cells, especially the 
CD4 fraction, expressed NKG2D ligands (NKG2D-L) not normally seen on T cells. 
NKG2D-L upregulation was further enriched on CD4 T cells in HBV-infected livers 
compared to the circulation and control livers. Oxidative stress, one noteworthy 
pathogenic feature of HBV infection, was demonstrated to recapitulate the T cell 
NKG2D-L upregulation pattern seen in patients with chronic hepatitis B (CHB). NK 
cells from patients with CHB maintained NKG2D expression and their increased 
activation and cytotoxicity could be driven by NKG2D-L expressing cells. In line 
with the distinctive features of T cells and NK cells in CHB, we discovered a 
positive correlation between activation of NKG2D+NK cells and the NKG2D-L 
(MICA/B) levels on CD4 T cells. Additionally, the pro-inflammatory cytokine IFN-α, 
used in HBV treatment, was shown to favour for NKG2D-mediated regulation. 
To conclude, we provide the first ex vivo evidence that human T cells, particularly 
those sequestered within tissues, can become visible to the stress surveillance system 
by the induction of NKG2D-L. We show that in active CHB, T cells upregulate 
NKG2D-L which can drive NK cell activation and cytotoxicity via the NKG2D 
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pathway. These interactions may be triggered by aberrant oxidative stress and result 
in a homeostatic response of "damage removal", thereby limiting T cell antiviral 
immunity. Therefore, efforts to manipulate the HBV-infected liver milieu in order to 
decrease T cell oxidative stress and diminish constraints from NK cells and the 
NKG2D pathway should be considered to reduce HBV pathogenesis and promote 
immunity.  
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Chapter 1 Background of the Study  
1.1 Overview of Hepatitis B Virus Infection 
Hepatitis B virus and its global health impact 
HBV is a serious global health issue with roughly 30% of the worldwide population 
presenting serological evidence of ongoing or previous HBV infection. According to 
the WHO 2015 report, it is estimated that around 240 million people are chronic 
HBV carriers and more than 700,000 annual deaths are attributed to the resultant 
liver diseases, cirrhosis and hepatocellular carcinoma (2015; Trepo et al., 2014). 
HBV is usually transmitted via blood or semen. Therefore, vertical transmission 
from infected mothers to neonates, or horizontal transmission from unprotected 
sexual behavior, contaminated needles, instruments, or blood product exposure are 
all common infection sources (2015; Trepo et al., 2014). 
HBV is a hepatotropic, partially double-stranded DNA virus belonging to the 
Hepadnaviridae family. Acting as a "stealth virus" with non-cytopathic properties, 
HBV can efficiently infect a large proportion of hepatocytes and establish persistent 
liver infection (Protzer et al., 2012; Seeger and Mason, 2000; Yoo et al., 1987). 
The HBV virion enters hepatocytes through the sodium taurocholate cotransporting 
polypeptide (NTCP) and releases its nucleocapsid into the cell cytoplasm (Yan et al., 
2012; Zoulim and Locarnini, 2009) (Figure 1.1). The virus relaxed circular DNA 
(rcDNA) is then transported to the nucleus, where the HBV genome is transformed 
into a transcriptional template called covalently closed circular DNA (cccDNA) 
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(Seeger and Mason, 2000; Urban et al., 2010). HBV cccDNA residing within the 
hepatocyte nucleus is fundamental for the virus maintenance and replication.  
 
Figure 1.1 Schematic depiction of the HBV replication cycle (*figure modified 
from Zoulim and Locarnini, 2009). 
 
During replication, HBV reverse transcriptase converts pre-genomic RNA 
intermediates into virus DNA, an error-prone step with high mutation tendency. The 
viral messenger RNA (mRNA) codes for the various structural and non-structural 
proteins. The pre-core protein is processed in the endoplasmic reticulum (ER) and 
secreted as HBeAg. A small non-particulate protein, HBxAg, capable of 
transactivating the transcription of both cellular and viral genes, is important for viral 
replication and carcinogenesis. The envelope protein presenting as the outer surface 
of the virion or in smaller tubular and spherical forms is referred to as HBsAg. The 
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core protein is essential for assembly of nucleocapsid particles which contain HBV 
DNA and DNA polymerase (Beck and Nassal, 2007; Seeger and Mason, 2000, 2015; 
Yokosuka and Arai, 2006). A typical feature of HBV life cycle is the persistently 
high-level viral protein secretion (Ganem and Prince, 2004), with different clinical 
implications. By definition, patients who remain HBsAg-positive longer than 6 
months are chronic HBV carriers. On the other hand, serum HBsAg usually becomes 
undetectable with protective HBsAb appearance within 6 months in acute resolved 
patients. The secreted nucleocapsid protein, HBeAg was widely used as an indicator 
for viral replication and infectivity; however there are now many patients with 
eAg-negative mutants (see below) who can also have high levels of viral replication 
(Ganem and Prince, 2004; Trepo et al., 2014).  
 
Clinical course of HBV infection 
The outcome of HBV infection is mainly dependent on age; infection during 
adulthood is usually resolved spontaneously with lifelong immunity development 
and only less than 5% of cases result in chronicity. On the other hand, around 95% of 
neonates and 30% of children become long-term carriers, bearing the risk of liver 
complications and cancer progression (Trepo et al., 2014).   
Clinical symptoms of acute hepatitis B (AHB) can be slight or subclinical, especially 
in children or young adults (Trepo et al., 2014). Non-specific symptoms such as 
malaise, anorexia, abdominal discomfort, or jaundice are common complaints. Due 
to the prolonged and clinically indistinct incubation period of HBV infection, human 
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immunological studies in acute or pre-symptomatic patients are challenging and 
difficult to access (Dunn et al., 2009; Webster et al., 2000). Patients with chronic 
HBV infection can be broadly divided into four clinical phases (Figure 1.2) (Liaw 
and Chu, 2009; Lok, 2007). Particularly, when HBV is acquired before early 
childhood, patients will firstly experience the asymptomatic immunotolerant 
phase characterized by extremely high viral loads (HBV DNA usually >107 IU/mL) 
but normal serum alanine aminotransferase (ALT), and no/minimal liver pathology. 
This period can last for years until unknown triggers precipitate the development of 
the immune clearance phase, showing a decrease of HBV DNA with active 
hepatitis and liver function abnormalities. Some patients going through this phase 
successfully suppress HBV replication to a lower viral load (<103 IU/mL) and move 
into the inactive carrier phase, presenting long-term normalisation of ALT and 
seroconversion of HBeAg to HBeAb (Liaw and Chu, 2009; Lok, 2007). Generally, 
the prognosis of patients in the inactive carrier phase is favorable, particularly if this 
state is achieved early. However, in spite of HBeAg seroconversion, roughly 30% of 
patients will experience HBV reactivation with fluctuating viral loads and 
intermittent hepatic flares. In the HBV reactivation phase, these HBeAg-negative 
patients with precore or basal core promoter mutations have an increased risk of liver 
cirrhosis and cancer development (Liaw and Chu, 2009; Lok, 2007). 
 
  
19 
 
Figure 1.2 Natural course of chronic HBV infection (*figure modified from 
Lok AS, 2007). 
 
Current treatment and limitations 
Although several potent, first-line anti-HBV drugs are available nowadays, including 
interferon-based regimens (conventional or pegylated-interferon α, PEG-IFNα) and 
nucleos(t)ide analogues (lamivudine, adefovir, entecavir, telbivudine, and tenofovir), 
complete HBV eradication and sustained off-treatment responses are still rarely 
achieved (Papatheodoridis et al., 2008).  
Interferon has both anti-viral and immunomodulatory effects. Recent research has 
illustrated that interferon-α is able to promote non-cytotoxic cccDNA eradication in 
HBV-infected cells through activating the apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like 3A (APOBEC3A) cytidine deaminase (Lucifora et al., 
2014). However, many adverse effects, such as fatigue, influenza-like symptoms, 
Immunotolerant+
phase!
Immune+clearance+
phase!
Inac0ve+carrier+
phase!
Reac0va0on+
phase!
  
20 
bone marrow suppression and even severe hepatitis flares have limited interferon 
clinical usage (Papatheodoridis et al., 2008; Trepo et al., 2014).  
On the other hand, nucleos(t)ide analogues are generally safe and well-tolerated in 
patients. These anti-viral regimens can efficiently suppress HBV replication by 
inhibiting HBV polymerase/reverse transcriptase activity. Hence, without the 
advantage of directly targeting cccDNA, virus relapse after nucleos(t)ide analogue 
discontinuation is common. Furthermore, in view of the HBV high mutation and 
error-prone tendency, drug resistance development is also another key concern of the 
nucleos(t)ide analogue treatment (Papatheodoridis et al., 2008; Trepo et al., 2014), 
although tenofovir and entecavir, the mainstay of HBV treatment in the UK, have 
high genetic barriers to resistance. The long-term or even life-long maintenance 
therapy usually required with nucleos(t)ide analogues carries a huge cost burden as 
well as risks of non-compliance and longterm toxicity (Lampertico et al., 2015). 
Interferon-based and nucleos(t)ide analogue regimens have divergent effects on 
immune responses (Lampertico et al., 2015; Thimme and Dandri, 2013). Work from 
our group has shown that PEG-IFNα therapy significantly enhanced the 
pro-proliferative cytokine IL-15 induction and CD56bright NK cell expansion. Within 
expanded NK cells, boosting effects of PEG-IFNα were also reflected in increased 
IFN-γ production, activating receptor NKp46 and TRAIL upregulation. Moreover, 
the functional CD56bright NK cell expansion correlated with patient peak virological 
responses, further suggesting that PEG-IFNα anti-viral effects involve augmentation 
of innate immunity (Micco et al., 2013).  
  
21 
Conversely, a marked reduction of CD8 T cells was noticed during PEG-IFNα 
therapy. These findings, along with other group results, revealed that PEG-IFNα did 
not improve HBV-specific T cell response and had no effect on the inhibitory 
molecule (PD-1 or CTLA-4) expression of T cells (Micco et al., 2013; Penna et al., 
2012). Therefore, interferon therapy appears to have relatively limited benefits on T 
cell immunity.  
Unlike PEG-IFNα, long-term treatment with nucleos(t)ide analogues can contribute 
to improvement of HBV-specific CD8 T cell functions. As in results reported by 
Boni et al in 2012, greater expansion potential of HBV-specific CD8 T cells was 
observed, at least in the few patients with complete antigen clearance (HBsAg 
seroconversion), upon nucleos(t)ide analogue treatment compared to those in 
untreated patients or patients who had not seroconverted (Boni et al., 2012). 
Differently, NK cell functional recovery was not noted in patients undertaking 
nucleos(t)ide analogues (Peppa et al., 2010).  
In summary, PEG-IFNα and nucleos(t)ide analogues seem to have different but 
complementary capabilities to restore impaired innate and adaptive immunity in 
chronic HBV infection. Thus, considering the complex nature of the virus and 
unsatisfactory treatment outcomes, a breakthrough in HBV management is in urgent 
demand and requires further study.  
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1.2 Immune Response Defects in HBV Infection  
Tolerogenic liver environment exploited by HBV 
The liver is a vital organ, carrying out numerous important functions, such as 
metabolism, detoxification, and immunomodulation to maintain homeostasis and 
health (Crispe, 2009; Protzer et al., 2012; Sheth and Bankey, 2001). Due to the 
constant exposure to gastrointestinal antigens derived from food, the liver has 
immunotolerant features, presumably to avoid reacting to harmless antigenic material. 
In fact, various cells within the liver together with the cytokine milieu predispose the 
tolerogenic microenvironment to dampen humoral and cellular immunity (Crispe, 
2003; Kmiec, 2001; Knolle et al., 1999; Tu et al., 2008). Nevertheless, this 
physiological trait can be exploited by hepatotropic pathogens to establish persistent 
infection.  
Hepatitis B virus (HBV) is one of the most well known intrahepatic pathogens, 
which can efficiently infect hepatocytes and lead to chronic liver pathology and 
lethal complications, including liver cirrhosis and cancer (Protzer et al., 2012). By 
virtue of previous research, host-virus interactions following infection could be 
briefly depicted in a model involving the rapid anti-viral cytokine responses, then the 
early innate cellular defence, and the final viral clearance by mature adaptive 
immunity development (Figure 1.3A) (Alexandre et al., 2014; Murphy et al., 2012; 
Openshaw and Tregoning, 2005).  
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Figure 1.3 Schematic depiction of immune responses during virus infection. 
A Time course of virus titer and immune responses during MCMV 
infection (virus titer-dashed black line; cytokine response-pink line; 
NK cell response-gray area; T cell response-green line; *figure 
modified from Murphy et al. Janeway’s Immunobiology, 8th edition). 
B Time course of virus titer and immune responses during acute and 
chronic HBV infection (virus titer-dashed black line; NK cell 
response-gray area; CD4 T cell response-red line; CD8 T cell 
response-green line; antibody response-blue line; *figures modified 
from Isogawa M and Tanaka Y, 2015). 
 
However, HBV is a cunning virus, one that has evolved to elude and debilitate the 
host immunity in diverse ways and can establish long-term infection in the liver. 
Thus, in view of the widespread devastating influence of HBV and current 
unsatisfactory treatment options, it is crucial to understand these defects in 
liver-specific immunity for better virus control and disease resolution.  
 
HBV as a “stealth virus” slipping through the front-line cytokine defence  
The hallmark of early defence against viral infection is the production of type I 
interferons (IFNs) which can directly inhibit virus and also support NK cell function, 
promote dendritic cell maturation, and assist adaptive T cell responses (Dalod et al., 
2003; Lanier, 2008; Tough et al., 1996). However, unlike the common immune 
HBV
An&'viral-
cytokines:--
Type-I-IFN,--
TNFα,-IL'12
NK-cell--
Immunity
T-cell-
Immunity
Virus-Titer
2 4 6 8 10
Time-aCer-viral-infec&on-(days)
HBV
Time-aCer-infec&on
Early-priming-
of-CD4-T-cells-
No-early-priming-
of-CD4-T-cells-
CD8-T-cell-
immunity An&'HBs
Acute-self'limited-infec&on
Chronic-infec&on
BA
  
24 
response to acute viral infection, previous in vivo chimpanzee studies revealed IFN-I 
responsive genes in the liver were barely detectable during the early HBV entry and 
expansion phase (Wieland et al., 2004). Similarly, the serum IFN-α concentrations 
remained low with no significant upregulation observed at the time of peak viraemia 
in acute HBV patients compared to HBV resolved patients and healthy controls 
(Dunn et al., 2009). In contrast, self-limiting hepatitis A virus (HAV) infection 
presenting higher serum IFN-α levels; thus HBV acts like a “stealth virus” showing 
mild/minimal clinical symptoms and defective IFN responses in the early stage of 
infection (Protzer et al., 2012; Wieland and Chisari, 2005). Since the extreme 
sensitivity of HBV to IFN-α has been proven in transgenic mouse models (McClary 
et al., 2000; Wieland et al., 2000), this inherent strategy for evading innate 
recognition probably reflects HBV replication within the nucleus, shielded from 
many pattern recognition receptors. In addition, recent research suggests there may 
be a component of active suppression of innate immunity during HBV infection 
(Bertoletti et al., 2010).  
 
Pathogenic role rather than protective role of the NK cell 
NK cells, the largest (30-40%) component of intrahepatic lymphocytes, can regulate 
various immune interactions and immunopathology (Doherty et al., 1999; Shi et al., 
2011). Unlike in the peripheral counterpart, liver NK cells are highly activated and 
comprise a larger CD56bright population. Recent murine research implicates those 
intrahepatic NK cells with high CXCR6 expression and a relative immature 
phenotype as a particular liver-resident lineage, which could mediate “memory-like” 
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responses to viruses or haptens (O'Leary et al., 2006; Paust et al., 2010). Since HBV 
infects and replicates within the liver, NK cell immunity is likely to play a crucial 
role in this hepatotropic virus invasion. However, though NK cells have been shown 
to efficiently inhibit HBV replication in several animal models (Guidotti et al., 1999; 
Kakimi et al., 2000; Yang et al., 2002), delayed and suppressed NK cell effector 
functions were witnessed in patients during the early replication phase of HBV 
infection which, coincidentally, were in line with the immunosuppressive cytokine, 
IL-10 levels (Dunn et al., 2009; Fisicaro et al., 2009).  
Indeed, despite NK cell frequency appearing unaffected in some studies, their 
responses in HBV infection are dysfunctional and skewed (Bonorino et al., 2009; 
Peppa et al., 2010). First of all, defective cytokine production by NK cells has been 
observed in several studies of CHB patients, with impaired IFN-γ production directly 
reducing NK cell anti-viral activity as well as diminishing their support for T cell 
immunity (Oliviero et al., 2009; Peppa et al., 2010; Tjwa et al., 2011). A number of 
pathologic factors in chronic HBV infection have been suggested to be responsible 
for NK cell functional defects, such as disturbed pDC/NK cell interplay by HBV, 
Kupffer cell suppression via galectin-9, IL-10, and TGF-β, or aberrant 
activating/inhibitory signals for NK cell receptors (Ju et al., 2010; Nebbia et al., 2012; 
Peppa et al., 2010; Shi et al., 2012; Sun et al., 2012; Tu et al., 2008).  
However, in addition to dysfunctional cytokine production, the preserved 
cytotoxicity of NK cells has been shown to participate in various immunopathology 
(Peppa et al., 2010; Zhang et al., 2011b). In CHB, NK cells can cause liver injury in 
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a TNF-related apoptosis inducing ligand (TRAIL) dependent manner (Dunn et al., 
2007). Besides the TRAIL pathway, Fas and NKG2D pathways were also implicated 
in NK cell-mediated hepatocyte damage (Okazaki et al., 2012; Zou et al., 2010). 
Furthermore, recent work from our group also illustrated that through 
TRAIL-dependent cytotoxicity, NK cells can kill HBV-specific CD8 T cells to 
constrain anti-viral immunity in patients with chronic HBV infection (Peppa et al., 
2013). Thus, considering the current evidence, the NK cell seems to play a more 
pathogenic rather than protective role in HBV infection.  
 
Crucial but defective anti-viral T cells in chronic HBV infection 
It is widely accepted CD4 T cells are crucial for supporting competent adaptive 
immunity in viral infection. Consistently, current evidence also suggests a close link 
between CD4 T cell immunity and the outcome of HBV infection (Chisari and 
Ferrari, 1995; Guidotti et al., 2015b).  In contrast to the vigorous and multi-specific 
CD4 T cell responses to HBV in resolved patients, CD4 T cells in chronic HBV 
carriers have a weak and narrow repertoire of anti-viral responses and poor 
proliferative capacity (Figure 1.3B) (Ferrari et al., 1991; Ferrari et al., 1990). 
The pivotal role of CD4 T cells is also clearly supported by the in vivo clinical 
observation, where HIV-infected, low CD4 T cell patients are more prone to develop 
HBV chronicity in horizontal transmission cohorts (Hadler et al., 1991; Puoti et al., 
2006). Additionally, the previous in vivo chimpanzee models even more specifically 
demonstrated the necessity of CD4 T cells in HBV infection. Accordingly, although 
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CD4 T cell depletion at the peak of HBV viraemia did not hinder the eventual 
disease resolution, depletion of CD4 T cells prior to HBV infection did both 
quantitatively and qualitatively impair HBV-specific CD8 T cells and lead to 
consequent HBV persistence (Asabe et al., 2009; Thimme et al., 2003). Therefore, 
these results point to CD4 T cells indirectly contributing to virus control, probably 
through priming and supporting anti-viral immunity, such as by IL-2 secretion or by 
promoting APC co-stimulation for HBV-specific CD8 T cells (Bertolino et al., 2001; 
Castellino and Germain, 2006; Limmer et al., 2000). 
Nevertheless, some studies also suggest CD4 T cells can modulate the inflammatory 
response. The recently defined T-helper 17 (Th17) CD4 T cell subset increases in 
CHB patients and can produce IL-17 and IL-22 to exacerbate disease activity (Zhang 
et al., 2010; Zhang et al., 2011a). By contrast, regulatory CD4 T cells (Treg) with the 
ability to suppress T cell expansion and survival are implicated as having 
anti-inflammatory properties (Manigold and Racanelli, 2007; Xu et al., 2006).   
Apart from CD4 T cells, CD8 T cells also have decisive significance in HBV 
infection. The most solid evidence provided in HBV chimpanzee models reveals that 
depletion of CD8 T cells at the peak of infection impeded HBV clearance until T cell 
re-induction (Thimme et al., 2003). Additionally, human and chimpanzee studies 
demonstrated that CD8 T cells could potently eliminate HBV via non-cytolytic 
anti-viral cytokines such as IFN-γ and TNF-α (Guidotti et al., 1999; Maini et al., 
2000; Phillips et al., 2010). 
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Similar to the weak and narrowly focused CD4 T cell responses to HBV, CD8 T 
cells in CHB patients lack the vigorous and multi-specific anti-viral immunity 
required for HBV clearance (Figure 1.3B) (Bertoletti and Ferrari, 2012; Boni et al., 
2007; Fisicaro et al., 2010; Rehermann et al., 1995). Moreover, the cytopathic 
activity of CD8 T cells has been described to cause liver damage (Ando et al., 1993; 
Isogawa et al., 2005; Maini et al., 2000). Surrounded by persistent, high antigen load 
and bombarded with excessive inhibitory signals, liver-infiltrating lymphocytes are 
driven to anti-viral exhaustion and in turn become pathogenic in the HBV-infected 
liver. Noticeably, evidence from transgenic mouse and human studies showed that 
when HBV-specific CD8 fail to control virus they initiate liver damage, which is 
then mainly caused by the non-HBV-specific subset (Guidotti and Chisari, 2006; 
Isogawa et al., 2005; Maini et al., 2000; Nakamoto et al., 1997). Thus, defective and 
inappropriate CD8 T cell responses can be a key factor in the failure of HBV control 
and varying degrees of liver pathology. Hence, to improve HBV control, the future 
therapeutic approaches should aim to reverse negative suppression and re-direct the 
anti-viral immunity of T cells.  
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1.3 Overview of Human NK Cells   
NK cell development and features  
NK cells, as a part of innate immunity, are large granular lymphocytes having the 
ability to kill targets without the need for specific sensitisation or immunization. 
Indeed, experiments in mice have shown NK cells can rapidly exert effector 
functions to contain virus infections, providing more time for adaptive immunity to 
fully develop and mature (Caligiuri, 2008; Vivier et al., 2008). In contrast, a lack of 
NK cells in the early phase of infection can lead to greater virus replication and 
serious consequences (Lee et al., 2007; Orange, 2002; Scalzo et al., 2007).  
Intriguingly, recent research has extended the border of NK cells to the gray zone 
between innate and adaptive immunity, since their "memory-like" behavior exhibits 
antigen-specific features (O'Sullivan et al., 2015; Sun et al., 2011). Moreover, recent 
studies indicate that NK cells do not always react in an invariant manner, but can 
potentially adapt to the surrounding environment and modify their functions 
correspondingly (Vivier et al., 2011). Thus, the sophisticated capabilities of NK cells 
highlight their immune significance in pathogen defence and tumour surveillance. 
Generally, the surface phenotype of human NK cells lacks CD3 but possesses CD56, 
a neural cell adhesion molecule (NCAM). While the phenotype of NK cells varies 
extensively across species, one highly conserved natural cytotoxicity receptor (NCR) 
NKp46 serves as a good marker for mammalian NK cells (Caligiuri, 2008; Walzer et 
al., 2007).  
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It is widely recognised that human NK cells primarily develop within the bone 
marrow. However, current evidence points out some NK precursor cells with 
differentiation potential can be found in certain secondary lymphoid organs including 
the liver (Eissens et al., 2012; Galy et al., 1995; Miller et al., 1994; Moroso et al., 
2011; Shibuya et al., 1993). Although the development of human NK cells has not 
been fully understood, recent research has depicted their differentiation pathway 
based on the sequential acquisition of functional capabilities and specific phenotypic 
markers. These include the differentiation progression from bone marrow-derived 
hematopoietic stem cells to the pro-NK (CD34+CD117-CD94-) stage, pre-NK 
(CD34+CD117+CD94-) stage, immature iNK (CD34-CD117+CD94-) stage, and the 
stage of NK cells presenting CD34-CD117+/-CD94+ corresponding to the NK cell 
CD56bright subset (Freud et al., 2005; Freud et al., 2006; Sun and Lanier, 2011).  
CD56bright NK cells have greater levels of adhesion molecules L-selectin (CD62L) 
and lymphoid homing receptor CCR7 and are preferentially enriched in secondary 
lymphoid tissue (SLT), such as lymph nodes, tonsils, and the liver. In fact, CD56bright 
NK cells are conventionally regarded as the principal source of NK cell-derived 
cytokines, such as IFN-γ, TGF-β, IL-10, but lack the low-affinity Fcγ receptor CD16 
and cytotoxic granules perforin and granzymes (Caligiuri, 2008; Cooper et al., 2001; 
Vivier et al., 2008).  
In contrast, the CD56dim subset, comprising the majority of NK cells in the bone 
marrow, blood and the spleen displays dominant cytolytic capacity in line with its 
abundance of perforin and granzymes, as well as high levels of CD16 relevant to 
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antibody-dependent cellular cytotoxicity (ADCC) (Caligiuri, 2008; Cooper et al., 
2001; Vivier et al., 2008).   
The findings of recent definitive studies support that CD56dim NK cells represent a 
phenotypically more mature subset and are directly derived from CD56bright NK cells 
(Chan et al., 2007; Lanier et al., 1986; Ouyang et al., 2007; Romagnani et al., 2007). 
However, considering their disparate phenotype features and different functional 
behaviors, whether CD56bright and CD56dim NK cells can be satisfactorily defined 
into two successive differentiation stages remains unanswered.  
 
NK cell function and regulation 
Human NK cells in the circulation are relatively short-lived with an estimated 
turnover time of about 2 weeks (Zhang et al., 2007). Although in viral infection, NK 
cells can offer rapid non-specific defence before adaptive immunity is fully activated, 
their effector functions are mainly dependent on the background cytokine milieu and 
the integrated signals received from the surface activating and inhibitory receptors 
(Vivier et al., 2008).  
IL-2 is well-known to be able to promote proliferation, cytotoxicity and cytokine 
production of NK cells, whilst other cytokines such as type I IFN, IL-12, IL-15, and 
IL-18 are potent activators for NK cell effector function as well (Vivier et al., 2004; 
Vivier et al., 2008; Walzer et al., 2005).  
Distinct surface receptors also tightly regulate NK cell activity. NK cells have a great 
variety of germline-encoded activating and inhibitory receptors (Bryceson et al., 
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2006a; Lanier, 2005). Broadly, there are three major families of natural killer 
receptors (NKR). One superfamily is killer cell immunoglobulin-like receptors (KIR) 
recognising classical major histocompatibility complex (MHC) class I molecules, 
like HLA-A, B, and C. Another is the C-type lectin-like receptors, consisting of 
seven NKG2 family members (NKG2A, B, C, D, E, F and H), which recognise MHC 
class-I like molecules or non-classical MHC class-I molecules. Thirdly, the natural 
cytotoxicity receptor (NCR) superfamily has members such as NKp30, NKp44, 
NKp46, and NKp80 (Figure 1.4). 
 
 
Figure 1.4 Schematic representation of three major families of NK cell 
receptors and their structure (*figure modified from the poster of 
Eric Vivier and Sophie Ugolini in Nature Reviews). 
 
In general, NK cell cytotoxicity is adequately controlled by the balance of signals 
from NK cell receptors to ensure elimination of targets, but not healthy cells. 
Ordinarily, killing of healthy "self" cells by NK cells is prevented by dominant 
inhibitory receptors recognising "self" MHC class I molecules on the cells. This 
MHC class I based self-tolerance attribute is essential for the NK cell education 
process before NK cells achieve functional competence (Caligiuri, 2008; Hoglund 
and Brodin, 2010; Kim et al., 2005; Vivier et al., 2008).  
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NK cells perform a complementary role to cytotoxic T cells in host immunity, 
effectively targeting "altered-self" cells with downregulated self-MHC class I 
molecules and recognising cells with stimulatory signals surpassing the inhibitory 
threshold (Caligiuri, 2008; Long et al., 2013; Sun and Lanier, 2011; Vivier et al., 
2004). While facing dangerous assaults and pathologic stress, NK cells can exert 
cytotoxicity by exocytosis of perforin and granzymes or by expressing death ligands, 
such as the TNF-related apoptosis-inducing ligand (TRAIL) and Fas ligand (Fas-L) 
to eradicate affected cells (Smyth et al., 2005).    
 
Immune perspective of liver NK cells  
Current evidence indicates that to maintain regional health and local immune 
homeostasis, organ-specific NK cells carry divergent phenotypic and functional 
features different from bone marrow-derived conventional NK cells (Shi et al., 2011; 
Yokoyama et al., 2013).  
Unlike peripheral NK cells that only account for a minor fraction of total circulating 
lymphocytes, hepatic NK cells represent the largest (30-40%) lymphocyte population 
in the human liver (compared to 5-10% in mouse liver) (Doherty et al., 1999; Shi et 
al., 2011). With preferential residence within the hepatic sinusoidal space, liver NK 
cells intimately contact other lymphocytes and non-parenchymal cells to modulate 
liver immunology (Figure 1.5) (Krueger et al., 2011).  
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Figure 1.5 Schematic diagram of the hepatic sinusoid structure and its cellular 
components (*figure kindly provided by Dr. Anna Schurich, Maini 
group). 
 
Since the liver is constantly exposed to gut-derived antigens, hepatic NK cells are 
usually maintained in a functionally hyporesponsive state (Tu et al., 2008). In fact, 
many studies have proposed that the inhibitory receptor NKG2A on hepatic NK cells 
may contribute to the tolerogenic liver environment (Krueger et al., 2011). Research 
in patients with chronic hepatitis C suggests the increased NKG2A on NK cells may 
unfavorably facilitate HCV persistence by restraining anti-viral T cell immunity 
(Jinushi et al., 2004; Nattermann et al., 2006). Similarly, previous murine HBV 
models also demonstrated that elevated NKG2A on hepatic NK cells positively 
correlates with viral loads and can impede HBV clearance (Li et al., 2013).  
Additionally, the intrahepatic cytokine milieu greatly impacts NK cell function. For 
example, IL-10 secreted from Kupffer cells has been shown to suppress NK cell 
activation and effector function (Jinushi et al., 2007; Krueger et al., 2011). However, 
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this IL-10-mediated NK cell suppression has been implicated in avoiding excessive 
hepatic damage during liver inflammation.  
On the other hand, various cytokines in the inflamed liver are able to activate NK 
cells and drive their cytotoxicity (Burt et al., 2009; Kim et al., 2005; Shi et al., 2011). 
Evidence has revealed either endogenous, or therapeutic IFN-α can induce TRAIL 
upregulation on NK cells which could contribute to HBV or HCV elimination, but 
also collaterally inflict liver damage (Dunn et al., 2007; Stegmann et al., 2010). 
Moreover, in a TRAIL-dependent manner, NK cells have been known to kill 
HBV-specific T cells and hepatic stellate cells (Glassner et al., 2012; Peppa et al., 
2013).  
Notably, recent studies observed that a particular CXCR6-positive subset of hepatic 
NK cells manifests antigen-specific recall behaviors (Paust et al., 2010). Although 
difficulty accessing healthy liver tissue limits human liver research, many animal 
models have shed light on NK cell "memory-like" responses in this field. 
Specifically, upon haptens, virus-like particles, or vaccinia virus sensitisation, 
hepatic, but not splenic, NK cells exhibit distinct reactions akin to immunological 
memory (O'Leary et al., 2006; Paust et al., 2010; Paust and von Andrian, 2011). This 
phenomenon could be detected in mice lacking T cells and B cells, in which these 
"primed" NK cells remained long-lived and were able to mount a secondary response 
when re-exposed to the same stimuli. Furthermore, preferential clonal-expansion of 
NKG2C-positive NK cells in HCMV infection also suggests the existence of NK cell 
memory in humans (Foley et al., 2012; Lopez-Verges et al., 2011). However, the 
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immunobiological implications of this virus-specific proliferation are not yet fully 
determined, since NK cells in NKG2C-null patients are still competent to control 
HCMV infection (Beziat et al., 2013; Schlums et al., 2015). Therefore, more detailed 
mechanisms, such as identifying HCMV-mediated recognition molecules or 
clarifying the human NK cell specificity to other viruses apart from HCMV, require 
further investigation (O'Sullivan et al., 2015).  
In conclusion, it would be beneficial to consider all the particular features together, 
such as NK cell response to background circumstances or NK cell cross talk with 
other cells, to better understand pathology mechanisms and disease management.  
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1.4 Regulation and Interactions of the NKG2D Pathway 
NKG2D on human NK cells  
NKG2D (natural-killer group 2, member D) is one of the major activating receptors 
on NK cells, which can trigger cytokine production and cytotoxicity induction and 
participate in immunoregulation of infection, tumour surveillance, autoimmunity and 
transplantation (Bauer et al., 1999; Burgess et al., 2008). The significance of this 
receptor has come to light since diverse mechanisms for evading NKG2D-mediated 
recognition have been discovered in various viral infections and tumours 
(Lopez-Larrea et al., 2008; Obeidy and Sharland, 2009). 
Generally, effector functions of NK cells are defined by the cytokine milieu and 
integrated signals from inhibitory and activating receptors of NK cells. However, due 
to the activating signal upon NKG2D engagement surpassing other inhibitory inputs, 
NKG2D is viewed as a "master switch" and can predominantly determine the NK 
cell activation state (Obeidy and Sharland, 2009; Watzl, 2003).  
NKG2D is a C-type lectin-like receptor, first identified on NK cells and also 
expressed by NKT cells, γδT cells, and most CD8 T cells, though not normally seen 
on CD4 T cells (Bauer et al., 1999; Eagle and Trowsdale, 2007; Wu et al., 1999). In 
humans, the structure of NKG2D consists of a disulphide-linked homodimer, in 
which each monomer associates with two DAP10 adaptor proteins (Figure 1.6A). 
Unlike mouse NKG2D containing DAP10 or DAP12, the activity of human NKG2D 
is exclusively mediated through DAP10 intracellular signalling domains (Eagle and 
Trowsdale, 2007; Gilfillan et al., 2002).  
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Following engagement with NKG2D ligands, DAP10 transduces extracellular 
signals by phosphorylation of YXXM tyrosine-based motifs, resulting in recruitment 
and activation of the P85 subunit of phosphoinositide 3-kinase (PI3K) and the 
growth factor receptor-bound protein 2 (Grb2). The sequential signalling of PI3K 
and Grb2 can trigger the downstream MEK/ERK pathway to induce cytotoxicity, 
cytokine production, and cell proliferation (Burgess et al., 2008; Eagle et al., 2009; 
Vivier et al., 2004). 
 
 
Figure 1.6 Human NKG2D and its ligands (*figures modified from Eagle RA et 
al. 2009). 
A Structure of human NKG2D and its functions. 
B Structure of human NKG2D ligands (NKG2D-L). 
  
Nevertheless, while stimulation signals transduce through NKG2D, functional 
outcomes differ depending on various cell types and synergistic inputs (Diefenbach 
et al., 2002; Raulet et al., 2013). More specifically, NKG2D can serve as a primary 
activating receptor for activated NK cells in which NKG2D engagement alone is 
sufficient to induce NK cell-mediated cytotoxicity. Whereas, while NK cells are in a 
resting state, mere NKG2D stimulation is not enough to trigger full effector function. 
Thus, NKG2D signalling together with either other synergistic stimulation or 
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cytokine priming are necessary to fully activate natural cytotoxicity and cytokine 
secretion of naïve, resting NK cells (Bryceson et al., 2006b). 
In NK cells, once NKG2D-mediated exocytosis is triggered, cytotoxic granules such 
as perforin and granzymes can efficiently cause apoptotic and necrotic death of target 
cells through direct cytolysis, cellular caspase activation, or caspase-independent 
pathways (Hayakawa and Smyth, 2006).   
Although the expression of NKG2D on NK cells is observed in healthy individuals 
as well as in patients with CHB, previous findings have demonstrated various 
mechanisms influencing cellular NKG2D expression (Figure 1.7) (Burgess et al., 
2008; Oliviero et al., 2009; Zhang et al., 2011b; Zhao et al., 2012).  
Crucial for NK cell effector function and proliferation, IL-15 has been demonstrated 
to upregulate NKG2D on human NK cells (Dann et al., 2005). Moreover, in vitro 
stimulation with the pro-inflammatory cytokine, IFN-α was also shown to induce 
NKG2D expression on NK cells (Konjevic et al., 2010). On the other hand, IFN-γ 
and TGF-β were illustrated to have inhibitory effects on surface NKG2D (Castriconi 
et al., 2003; Lee et al., 2004; Zhang et al., 2004). Additionally, IL-21, secreted by 
activated CD4 T cells, has been shown to dampen DAP10 translation, thereby 
consequently decreasing NKG2D on NK cells (Burgess et al., 2006; Takaki et al., 
2005).  
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Figure 1.7 Schematic depiction of NKG2D/DAP10 regulation, in which IL-2, 
IL-15, TNF-α, and IFN-α are favourable for NKG2D expression, 
whereas IL-21, TGF-β, IFN-γ, and chronic stimulation of 
soluble/membrane-bound NKG2D-L can limit NKG2D/DAP10 
expression (*figure modified from Burgess SJ et al. 2008).  
 
In humans, another noteworthy mechanism responsible for NKG2D down-regulation 
is overexposure to NKG2D ligands. Since NKG2D is a vital component of tumour 
surveillance, some tumours may evade immune recognition by shedding or secreting 
soluble NKG2D ligands to induce endocytosis or degradation of NKG2D in NK cells 
(Holdenrieder et al., 2006a; Raffaghello et al., 2004; Salih et al., 2002). Previous 
research suggests placenta-derived soluble MICA/B in pregnant women utilizes a 
similar mechanism to protect and promote fetal survival by reducing unwanted 
NKG2D-mediated cytotoxicity (Mincheva-Nilsson et al., 2006). Consistently, 
chronic exposure to membrane-bound NKG2D ligands from tumour cells is also 
known to mediate down-regulation of NKG2D expression and reduction of cytotoxic 
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activity of NK cells (Coudert et al., 2005; Molfetta et al., 2014; Oppenheim et al., 
2005; von Lilienfeld-Toal et al., 2010). Therefore, a more comprehensive 
understanding of NKG2D regulation in infection or cancer settings is useful for 
therapeutic strategy development for restoration of normal NK cell function and 
immunity.  
 
Regulation and interactions of NKG2D-L 
In humans, eight NKG2D ligands, including MHC class I-chain related proteins A 
and B (MICA and MICB) and UL16 binding protein 1 through 6 (ULBP1-6) have 
been identified so far (Figure 1.6B) (Cosman et al., 2001; Groh et al., 1996). These 
ligands, with structure similarity to MHC class I proteins, are encoded by highly 
polymorphic genes and have different affinities and activating capabilities for NK 
cells (Eagle and Trowsdale, 2007; Raulet et al., 2013).   
Rarely expressed on healthy cells, NKG2D ligands are viewed as "stress molecules" 
due to the variety of pathologic stimuli responsible for their upregulation, such as 
infection, inflammation, tumour transformation as well as numerous metabolic and 
cellular stresses (Gonzalez et al., 2008; Shafi et al., 2011). However, to ensure 
stressed cell elimination without destruction of healthy cells, NKG2D ligand 
expression is tightly regulated at several stages, including transcriptional, 
post-transcriptional and post-translational levels (Figure 1.8) (Mistry and 
O'Callaghan, 2007; Raulet et al., 2013).  
 
  
42 
 
 
Figure 1.8 Mechanisms of NKG2D-L regulation (*figure modified from Mistry 
and O'Callaghan, 2007). 
 
Previous research has demonstrated that oxidative stress can enhance MICA/B 
transcription in colon carcinoma cells (Yamamoto et al., 2001). In addition, other 
studies also revealed oxidative stress participated in NKG2D-L upregulation on T 
cell blasts, human small bowel mucosa and airway epithelial cells (Allegretti et al., 
2013; Borchers et al., 2006; Rabinovich et al., 2000).  
Moreover, various genotoxic stimuli such as ionizing radiation, cisplatin or 
hydroxyurea treatment were also shown to induce NKG2D-L upregulation in human 
fibroblast cells (Gasser et al., 2005). Provoking a DNA-damage response (DDR) is 
widely recognised as an important contributor to NKG2D-L upregulation. Thus, 
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inhibition of DDR pathway mediators, ataxia-telangiectasia mutated (ATM) or ataxia 
telangiectasia and Rad3-related (ATR) kinases, can suppress NKG2D-L induction in 
experimental settings (Mistry and O'Callaghan, 2007; Raulet et al., 2013). 
Epidermal growth factor receptor (EGFR), another important post-transcriptional 
checkpoint for human NKG2D-L, has received great attention recently. Consistent 
with the positive correlation between the hyper-activated EGFR pathway and high 
expression of NKG2D-L on human carcinoma cells, EGFR activation can stabilize 
NKG2D-L mRNAs by relocalization of AUF1 proteins to subsequently secure 
post-transcriptional ligand expression (Vantourout et al., 2014). 
In addition, during the infection process, multiple NKG2D-L regulatory mechanisms 
can be initiated and altered diversely at different biogenesis and expression stages. 
As demonstrated in one previous transgenic HBV murine model, infected 
hepatocytes expressed higher NKG2D-L rendering them susceptible to 
NKG2D-mediated lysis (Chen et al., 2007). Contrary to this, recent research in a 
human hepatoma cell line revealed that HBsAg can induce several suppressive 
microRNAs to target MICA/B 3′-untranslated regions, thereby repressing their 
surface expression and avoiding NKG2D-mediated elimination (Wu et al., 2014). 
Another example is HCMV infection, in which viral immediate-early gene (IE1 or 
IE2) products are capable of inducing MIC gene transcription and surface MICA and 
MICB expression (Venkataraman et al., 2007). However, despite the induction 
effects of IE proteins, HCMV has evolutionarily acquired the ability to evade and 
suppress surface NKG2D-L levels via specific viral products, such as UL16, UL112, 
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UL142, US18, and US20 (Cosman et al., 2001; Dunn et al., 2003; Fielding et al., 
2014).  
Similarly, human immunodeficiency virus (HIV) has also developed evasion 
strategies to counteract NKG2D-L surface manifestation. The HIV protein Vpr has 
been shown to induce ATR kinase-dependent DDR and thereby upregulate 
NKG2D-L expression (Ward et al., 2009). However, HIV Vif can partly decrease 
DDR-mediated NKG2D-L induction to evade NK cell immune recognition (Norman 
et al., 2011). Moreover, HIV-1 Nef protein can also down-modulate surface 
expression of MICA, ULBP1 and ULBP2 on infected cells to escape NK 
cell-mediated killing (Cerboni et al., 2007a). These mechanisms to evade NKG2D-L 
expression further underscore the influential relevance of this pathway in host-virus 
interplay.  
Notably, cellular NKG2D-L expression can also be down-regulated by surface 
metalloproteinase (MMP) cleavage. This proteolytic shedding results in releasing 
various soluble NKG2D ligands, which have been detected in the sera of different 
cancer patient types (Raulet et al., 2013; Salih et al., 2006; Salih et al., 2002; 
Waldhauer and Steinle, 2006). Indeed, numerous cancer cells can adopt this strategy 
to evade NKG2D-mediated tumour surveillance, since this mechanism can not only 
directly decrease the NKG2D-L on the affected cells, but also lead to NKG2D 
internalization or lysosomal degradation by engaging with cleaved soluble ligands 
(Holdenrieder et al., 2006a; Mistry and O'Callaghan, 2007; Raffaghello et al., 2004). 
Moreover, circulating soluble ligands have been shown to correlate with poor 
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prognosis in certain cancers; the presence of soluble NKG2D-L in the sera may 
therefore serve as a prognostic indicator (Holdenrieder et al., 2006b; Paschen et al., 
2009). 
In summary, these regulation mechanisms altogether highlight the importance of the 
appropriate immune-alert system in maintaining host health. 
 
 
 
 
 
  
46 
Chapter 2 Materials and Methods 
2.1 Patients and Healthy Controls 
Blood samples were collected from 113 patients with CHB recruited from the 
Mortimer Market Clinic (NHS Trust), the Royal Free Hospital, University College 
London Hospital, and the Royal London Hospital (Barts Health NHS Trust). A total 
of 46 healthy control blood samples were obtained from staff or students at 
University College London. Surplus liver tissue was obtained from 36 patients with 
CHB who underwent diagnostic liver biopsies. Control liver samples were obtained 
from 11 non-HBV infected patients undergoing liver resections for colorectal 
metastases. Nine sets of transplant perfusates from cadaveric donor livers were 
collected during liver transplant surgery under the standard graft preparation 
protocols. The study was approved by the relevant ethical review boards and 
informed consent was obtained in writing from each individual or legally authorised 
representative.  All patients with CHB were HBsAg and HBV DNA positive longer 
than 6 months and were negative for HCV, HDV, and HIV infection. With the 
exception of 8 patients selected for longitudinal PEG-IFNα study, all patients were 
treatment naïve (Table 1). Liver inflammation was determined by serum alanine 
transaminase (ALT). 
 
  
47 
 
 
2.2 PBMC and Intrahepatic Lymphocyte Isolation 
Peripheral blood mononuclear cells (PBMC) were isolated from whole blood by 
standard gradient centrifugation on Ficoll-paque Plus (GE Healthcare). Intrahepatic 
lymphocytes (IHL) were obtained following gentle mechanical disruption of liver 
tissue prior to passing through a 70µm cell strainer (BD Bioscience) and multiple 
washes with RPMI 1640 (Invitrogen) as previously described (Dunn et al., 2007; 
Peppa et al., 2010). IHL from transplant perfusates were retrieved by 
density-gradient centrifugation as PBMC isolation. All cells in this study were 
maintained in complete RPMI medium composed of 500ml RPMI 1640 (Invitrogen) 
+ 10% fetal calf serum (FCS, Invitrogen) + 100U/ml Penicillin/Streptomycin 
(Invitrogen) + MEM essential amino acid (Invitrogen) + MEM non-essential amino 
acids (Invitrogen) + hydroxyethyl piperazineethanesulfonic acid (HEPES: Invitrogen) 
+ β-mercaptoethanol (Sigma-Aldrich) + sodium pyruvate (Invitrogen). 
 
HC (n=46) 
(PBMC) 
CHB (n=69) 
(PBMC, ALT≤60) 
CHB (n=44) 
(PBMC, ALT>60) 
CHB (n=8) 
(Pre-Tx Baseline) 
CHB (n=8) 
(*On PEG-IFNα Tx) 
CHB liver (n=36) 
(Biopsy) 
Control liver (n=9) 
(Perfusate) 
Age, years  
[mean±SEM] 
32.4±1.4 37.8±1.3 37.1±1.8 30.6±3.3 30.6±3.3 37.8±1.7 42.2±6.2 
Gender, F/M (%) 56.5/43.5 36.1/63.9 52.3/47.7 62.5/37.5 62.5/37.5 33.3/66.7 44.4/55.6 
ALT IU/L  
[median (IQ range)] 
n.a. 30.1 (21-37) 142.4 (80-168) 190 (96.3-299) 97.5 (46.3-230) 32.5 (24.3-76.8) n.a. 
HBeAg,  
Positive/Negative (%) 
n.a. 17.4/82.6 56.8/43.2 37.5/62.5 37.5/62.5 25/75 n.a. 
HBV DNA cps/ml  
[median (range)] 
n.a. 
1.4×103  
(20-3.2×108) 
4.1×106  
(860-1.1×109) 
6.1×107  
(7.8×104-4.5×108) 
1.2×103  
(540-5.5×106) 
4.5×103  
(20-6.5×105) n.a. 
Abbreviations:   SEM: standard error of mean;  IQ: interquartile; n.a.: not applicable; HC: healthy controls; CHB: chronic hepatitis B; Tx: treatment 
* On 3-4 months of PEG-IFNα treatment 
Table 1: Clinical data of study controls and patients.  
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2.3 Flow Cytometric Analysis and Gating Strategies 
For flow cytometric analysis, PBMC and IHL were washed with PBS and stained 
with a fixable Live/Dead dye (Invitrogen) at 4°C for 10 min, prior to Fc-Receptor 
blocking with FcR blocking reagent (Miltenyi Biotec, Germany). Surface staining 
was performed at 4°C for 30 minutes in the presence of saturating concentrations of 
monoclonal antibodies (mAbs), or isotype matched controls (Figure 2.1A and B). 
After fixation and permeabilisation with Cytofix/Cytoperm (BD Biosciences), 
intracellular staining (ICS) was conducted by using monoclonal antibodies in the 
presence of 0.1% saponin for 30 minutes at 4°C in the dark. Table 2 details 
anti-human monoclonal antibodies (mAb) used for the sequential gating strategy in 
this study. In general, NK cells, CD4 T cells, and CD8 T cells were identified as 
CD3-/CD56+, CD3+/CD4+, and CD3+/CD8+ populations, respectively (Figure 2.1A). 
Specific cell groups, such as MICA/B+, HLA-DR+, and IFN-γ+ populations were 
identified by using MICA/B mAb, HLA-DR mAb and IFN-γ mAb and the majority, 
negative stained cells, were viewed as global populations (Figure 2.1C). All samples 
were acquired on a LSR Fortessa or BD LSRII using BD FACSDiva6.0 (BD 
Bioscience). Data were analysed using FlowJo v.8 (TreeStar, Ashland, OR, USA).  
  
 
  
49 
 
 Antibody  Fluorochrome  Company  Dilution  Type of staining 
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Table 2: List of anti-human mAb used for flow cytometric analysis.  
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Figure 2.1 Representative gating strategies.  
A Sequential gating strategy used to identify CD4 T cells (left lower 
panel), CD8 T cells (middle lower panel), and NK cells (right lower 
panel).  
B Representative plots for NKG2D-L staining by using MICA/B mAb 
(right panel) and the matched IgG2a isotype (left panel).  
C Representative plots for gating MICA/B+ T cells (left panel), HLA-DR+ 
T cells (middle panel), IFN-γ+ T cells (right panel) and their counter 
parts, global T cells. 
 
2.4 HLA-A2-restricted Multimer Staining 
The frequencies of virus-specific CD8 T cells from HLA-A2 positive individuals 
were evaluated directly ex vivo by multimer staining as previously described (Pallett 
et al., 2015). Total PBMC were stained with APC-labelled CMV pp65 495-504 or 
HBV core 18-27, envelope 183-191, envelope 335-343, envelope 348-357, 
polymerase 455-463, and polymerase 502-510 dextramers (Immudex, Denmark) at 
37°C for 20 minutes in RPMI plus 10% fetal calf serum (Table 3). For gating 
virus-specific CD8 T cells, CD14/CD19 cells were first excluded and a control 
dextramer was used to identify true populations (Figure 2.2). Afterward, the cells 
were washed and pelleted for the sequential surface or intracellular staining as 
mentioned above.  
SS
C#
FSC#
FS
C%
A#
FSC%H#
Li
ve
/D
ea
d#
FSC#
CD
4#
CD3#
CD
8#
CD3#
CD
56
#
CD3#
CD
4#
MICA/B#
CD
4#
HLA%DR#
CD
4#
IFN%γ#
Global# MICA/B+# Global# HLA%DR+# Global# IFN%γ+#
6.5#
95#
99#
46#
34# 6.7#
1.25#4.84#0.24#
A" B"
CD
4#
Isotype##
C"
CD
4#
MICA/B#
0.02# 0.38#
CD4#T#cells# CD8#T#cells# NK#cells#
Lymphocytes# Singlet# Live#cells#
  
51 
 
 
 
Figure 2.2 Representative gating strategy for ex vivo dextramer staining.  
Representative plots of sequential gating strategy used to identify 
virus-specific CD8 T cells by staining of control dextramer (panel 5), 
CMV-specific dextramer (panel 6), and HBV-specific dextramers 
(panel 7). 
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Table 3: List of MHC class I-restricted multimers used for flow cytometric analysis.  
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2.5 Intranuclear FoxP3 Staining  
After surface staining, cells were first fixed with FoxP3 Buffer A (BD Bioscience) 
for 10 minutes at room temperature (RT). Following fixation, cells were then 
incubated in FoxP3 Buffer C (BD Bioscience) for 30 minutes at RT prior to the 
intranuclear FoxP3 mAb staining. After complete staining, cells were washed twice 
with PBS before flow cytometric acquisition. 
 
2.6 Cell Lines 
A B-lymphoblastoid cell line, C1R transfected with MICA*008 (C1R-MICA), was 
used as a source of cell-bound MICA (Tieng et al., 2002). A control cell line lacking 
MICA, C1R, served as a comparison (kindly provided by Professor Antoine Toubert, 
France). The MICA expression was verified by MICA/B mAb staining as described 
previously (Figure 2.3).  
 
Figure 2.3 Representative gating strategy for C1R/C1R-MICA cell staining.  
Representative plots of gating strategy for C1R/C1R-MICA cells and 
their MICA expression by using MICA/B mAb (panels 4 and 5) and the 
matched IgG2a isotype (panel 6). 
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2.7 NK cell and CD4 T cell Isolation  
Purification of NK and CD4 T cells or depletion of NK cells from PBMC was 
achieved by using NK cell or CD4 T cell Isolation Kits (Miltenyi Biotec) reaching 
95% mean depletion rate and purity, as per manufacturer’s instructions (Figure 2.4A 
and B).  
 
Figure 2.4 Representative plots of NK cell and CD4 T cell isolation.  
A Examples of NK cell purification (left panel) and NK cell depletion 
from PBMC (middle panel).  
B Example of CD4 T cell isolation (right panel). 
 
2.8 NKG2D Pathway Blockade  
NKG2D blockade was conducted by using anti-NKG2D mAb (0.5µg/ml, 
eBiosciences) without interference in NK cell viability. The efficacy and specificity 
were checked in the described C1R-MICA/NK cell co-culture system and after 
short-term stimulation of PBMC (Figure 2.5). 
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Figure 2.5 Representative plots of efficacy and specificity of NKG2D blockade.  
Examples of NKG2D blockade with anti-NKG2D mAb and summary 
results: CD107a response of purified NK cells upon NKG2D blockade 
in NK/C1R-MICA cell co-culture system (upper horizontal panel; 
n=10), HLA-DR response of purified NK cells upon NKG2D blockade 
in NK/C1R-MICA cell co-culture system (central horizontal panel; 
n=10), IFN-γ response of CD4 T cells upon NKG2D blockade in 
PBMC short-term stimulation system (lower horizontal panel; n=9); 
data analysed by Friedman test.   
	  
2.9 NK / Target cell Co-culture System 
To measure NK cell degranulation capacity, purified NK cells were co-cultured at 
1:1 ratio with target cells (C1R/C1R-MICA) at 37°C for 6 hours, in the presence of 
anti-CD107a-APC (BD Biosciences). Brefeldin A (1µg/ml, Sigma-Aldrich) and 
Monensin (1µg/ml, Sigma-Aldrich) were added after 1 hour of incubation. Where 
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indicated an anti-NKG2D blocking antibody or a control isotype antibody (0.5µg/ml, 
eBiosciences) was added at the onset of culture. NK cell cytotoxicity of target cells 
was evaluated in the same co-culture system using ICS for Caspase 3 in the presence 
of fixable Live/Dead staining (Invitrogen). Target cells were identified by CD19 
staining and their cytotoxicity was calculated as the sum of 
dead and Caspase 3+ populations, as shown in the illustration 
on the right. 
 
2.10 Short-Term Stimulation  
Where indicated, PBMC or NK-depleted PBMC were stimulated with HBV 
overlapping peptides (OLP) (15mer peptides overlapping by 10 residues spanning 
genotype D HBV core protein, 1µg/ml, JPT) in the presence of 40IU IL-2 (Miltenyi 
Biotec) in RPMI complete medium for 10 days at 37°C. IL-2 and medium were 
refreshed on day 4 of culture. On day 9, PBMC were re-stimulated with 1µg/ml HBV 
OLP overnight (16hr), in the presence of Brefeldin A (1µg/ml). In selected 
experiments a physiological ratio of freshly isolated NK cells was re-added in the 
culture at the onset of stimulation. Following short-term culture with HBV OLP, 
virus-specific T cells were identified for IFN-γ production via ICS. To examine the 
effect of NKG2D blockade on virus-specific responses, an NKG2D blocking mAb 
(0.5µg/ml, eBiosciences) was added with HBV OLP at the onset of culture and cells 
treated as described above.  
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2.11 Overnight Stimulation  
For overnight (16hr) culture of PBMC or IHL, 10 µg/ml HBV OLP were added and 
the cells were incubated at 37°C in the presence of Brefeldin A (1µg/ml). Where 
indicated these experiments were repeated in the presence of an NKG2D blocking 
antibody (0.5µg/ml, eBiosciences) added at the time of HBV OLP stimulation. 
HBV-specific T cells were identified as IFN-γ positive T cells by ICS.  
 
2.12 Hydrogen Peroxide Stimulation 
To investigate in vitro NKG2D-L stimulation, hydrogen peroxide (H2O2) solution 
(30%, BDH) was used to induce oxidative stress in cell culture. Purified CD4 T cells 
or PBMC from healthy controls were rested for 48 hours prior to the addition of 
H2O2 solution at varying concentrations (0.25mM-1mM) for the indicated time 
periods ranging from 0.5hr to 2hr. The NKG2D-L expression was examined by 
surface staining for NKG2D-L as mentioned above.  
 
2.13 Recombinant Human Interferon-α Stimulation 
NK cells isolated from PBMC of CHB patients or healthy controls were treated with 
1000 U/ml IFN-α (Alpha 2A, PBL InterferonSource) for four hours (Dunn et al., 
2007; Lucifora et al., 2014). Degranulation capability of NK cells was assessed 
directly after the IFN-α stimulation by CD107a staining. To examine the IFN-α 
induced NKG2D cytotoxicity of NK cells, untreated or IFN-α treated NK cells were 
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co-cultured with C1R-MICA cells at 1:1 ratio for 6 hours. Control C1R cells were 
also used to exclude other unspecific or allogeneic reactions. 
 
2.14 Statistical Analysis 
The non-parametric Mann-Whitney U test (for 2 groups), the Wilcoxon signed rank 
test (for 2 paired groups), Kruskal-Wallis (for >2 non-paired groups) or Friedman 
(for >2 paired groups) one-way tests were used as appropriate. Correlations between 
variables were analysed using Spearman’s rank correlation coefficient (r). P value < 
0.05 was considered to be significant for all tests. All figures are labelled as follows: 
* = p<0.05, ** = p<0.005, *** = p<0.001.  
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Chapter 3 Chronic HBV Infection renders T cells vulnerable to 
NKG2D-mediated regulation  
3.1 Introduction: Dysfunctional T cells in HBV infection  
Hepatitis B virus (HBV) is the most prevalent virus responsible for persistent liver 
infection and liver disease worldwide (Trepo et al., 2014). Although numerous 
anti-viral regimens are available for chronic HBV infection nowadays, sustained 
off-treatment responses with thorough virus control are rarely achieved (Lampertico 
et al., 2015). Nevertheless, unlike neonatal/perinatal HBV infection causing 
chronicity, the successful self-resolution of most adult-acquired HBV indicates that 
the mature immune system is capable of dealing with this virus, but is somehow 
restrained in chronic carriers (Trepo et al., 2014).  
 
Compared to the vigorous and multi-specific antiviral T cell immunity in HBV 
resolved patients, chronic HBV carriers have profoundly exhausted and depleted 
HBV-specific CD4 and CD8 T cell responses (Ferrari et al., 1990; Maini et al., 2000; 
Rouse and Sehrawat, 2010; Wang and Zhang, 2009). The importance of T cells in 
control of HBV suggested by these clinical observations has been supported by in 
vivo chimpanzee studies, which demonstrated that CD4 T cell depletion prior to 
HBV inoculation precluded adequate T cell priming leading to quantitatively and 
qualitatively compromised HBV-specific CD8 T cells and consequent HBV 
persistence (Asabe et al., 2009). Moreover, the fundamental role of HBV-specific 
CD8 T cells has also been established by the loss of virus control in acute HBV 
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infection following the CD8 T cell depletion in the chimpanzee model (Thimme et 
al., 2003).  
 
Since the defective nature of antiviral T cells is crucial to the outcome of HBV 
infection, multiple virus and host factors contributing to T cell failure have been 
intensively studied for future therapeutic advancement (Maini and Schurich, 2010; 
Ye et al., 2015). 
 
A hallmark of HBV infection is the large amount of viral particles and antigenic 
proteins, such as HBsAg and HBeAg, produced during the virus replication cycle. 
Persistent exposure to high antigen loads in the HBV-infected liver is postulated to 
be a key factor detrimental to T cell function (Maini and Schurich, 2010; Ye et al., 
2015). The rarely detectable HBV-specific CD8 T cells in patients with high viral 
load (>107 copies/ml) increased transiently following HBV suppression by anti-viral 
therapy (Boni et al., 2003; Boni et al., 2001; Webster et al., 2004) and in a more 
consistent manner within those achieving clearance of viral antigens associated with 
HBsAg seroconversion (Boni et al., 2012; Boni et al., 2015). In accord with a 
progressive and hierarchical loss of T cell effector function driven by the viral 
antigen load and stimulation duration, T cells in chronic HBV carriers display a 
pattern of poor proliferation, weak cytokine production and impaired cytotoxicity 
induction (Boni et al., 2007; Fisicaro et al., 2010; Maini et al., 2000; Wherry et al., 
2003; Younes et al., 2003).  
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Pronounced metabolic stress, including arginine deprivation and oxidative stress 
accumulation, is also a recognized feature of the chronically HBV-infected and 
inflamed liver milieu (Li et al., 2015; Pallett et al., 2015; Protzer et al., 2012; 
Shimoda et al., 1994). Recently, arginine depletion in HBV infection resulting from 
the injured hepatocytes and arginase-producing myeloid-derived suppressor cells 
(MDSC) has been shown to suppress T cell proliferation and IL-2 production as well 
as downregulate the CD3-ζ-chain of the TCR signalling complex (Das et al., 2008; 
Pallett et al., 2015). Furthermore, as a signature of HBV pathology, aberrant 
oxidative stress originating from HBV replication, viral products and chronic 
inflammation, may also have a negative impact on T cell function and survival 
(Ardolino et al., 2011; Hildeman et al., 1999; Kesarwani et al., 2013; Rabinovich et 
al., 2000). Collectively, these pathways of compromised T cell immunity highlight 
the importance of metabolic immunopathology in the setting of CHB.  
 
Apart from the abundant virus and pathogenic liver milieu background, the T cells 
themselves also upregulate various co-inhibitory molecules in chronic HBV infection, 
such as programmed cell death-1 (PD-1), T-cell immunoglobulin domain and mucin 
domain 3 (TIM-3), cytotoxic T lymphocyte-associated antigen-4 (CTLA-4/CD152), 
and CD244/CD48 (Maini and Schurich, 2010; Ye et al., 2015). Encountering 
overwhelming HBV antigens without adequate intrahepatic APC co-stimulation, 
outweighed by multiple co-inhibitory signals, could drive T cell exhaustion and 
hyporesponsiveness in the tolerogenic liver microenvironment (Isogawa et al., 2005; 
Maini and Schurich, 2010). Therefore, efforts to boost T cell responses by blocking 
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those co-inhibitory pathways have been widely researched, particularly the distinct 
progression on the PD-1/PD-L1 pathway.  
 
CD4 T cells have the essential role of supporting CD8 T cell responses and 
supporting the development of neutralizing antibodies. The exhausted characteristics 
of HBV-specific CD4 T cells, with notably high PD-1 expression, have been recently 
defined using DRB1*01-restricted MHC class II tetramers; their weak cytokine 
production and proliferation ability could be enhanced by PD-L1/2 neutralization 
(Raziorrouh et al., 2014). Along with CD4 T cells, HBV-specific CD8 T cells have 
also been proven to possess higher PD-1, particularly the intrahepatic fraction, 
showing greater restoration of anti-viral immunity upon PD-1/PD-L1 blocking via 
anti-PD-L1 antibodies (Boni et al., 2007; Fisicaro et al., 2010; Fisicaro et al., 2012).  
 
Besides functional exhaustion, the pro-apoptotic phenotype of HBV-specific CD8 T 
cells has also been revealed by gene microarray analysis. In CHB patients, the 
diminished and barely detectable HBV-specific CD8 T cells upregulate the 
apoptosis-inducing protein Bim (Bcl2-interacting mediator), increasing their 
susceptibility to death (Lopes et al., 2008). Through downstream blockade of the 
Bim pathway, recovery of HBV-specific CD8 T cells was achieved in vitro and 
directly ex vivo (Lopes et al., 2008). Thus, Bim-mediated apoptotic deletion is 
another important contribution to insufficient anti-HBV immunity and viral 
persistence. 
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Various suppressive cytokines and cellular interactions also take part in T cell 
regulation. Although the comprehensive role of liver-resident macrophages (Kupffer 
cells) in hepatitis B is still under investigation, they are known to predispose to liver 
immune tolerance and T cell suppression by PD-L1 expression and production of the 
immunosuppressive cytokine, IL-10 (Bilzer et al., 2006; Breous et al., 2009; Wu et 
al., 2009). Oxidative stress generated by Kupffer cells can also interfere with 
metabolic immune regulation by disrupting the local redox balance (Gabrilovich and 
Nagaraj, 2009; Hagen et al., 1994; Kesarwani et al., 2013) 
 
The contribution of classical FoxP3+ CD4 Treg (regulatory T cells) to T cell 
exhaustion is still controversial. Many studies have revealed that Treg, which can 
suppress HBV-specific T cells, are significantly higher in chronic HBV carriers than 
in resolved patients and controls (Manigold and Racanelli, 2007; Stoop et al., 2005; 
Yang et al., 2007). However, an inverse correlation between HBV disease activity 
and Treg frequency implies Treg may have beneficial anti-inflammatory effects 
(Manigold and Racanelli, 2007; Xu et al., 2006).  
 
NK cells are the largest component of intrahepatic lymphocytes and participate in 
early control of invading viral pathogens (Shi et al., 2011; Vivier et al., 2008). 
However, a newly growing focus is the dominant immunomodulatory capacity of 
NK cells in viral infection (Crome et al., 2013; Lang et al., 2012; Waggoner et al., 
2012; Waggoner et al., 2010). In the HBV-infected liver, NK cells have been 
demonstrated to cause liver damage through the TNF-related apoptosis inducing 
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ligand (TRAIL) dependent manner (Dunn et al., 2007). Moreover, our group recently 
found that in vitro NK cell depletion contributes to the enhancement of CD8 T cell 
immunity against HBV but not other control viruses (EBV, CMV, influenza virus). 
This suppressive regulation is a rapid and contact-dependent killing of HBV-specific 
T cells mediated by activated NK cells. Although the HBV-specific T cell deletion 
was shown to be TRAIL-dependent, the partial restoration upon TRAIL blockade of 
NK cells indicates other pathways were also involved in T cell killing and required 
further investigation (Peppa et al., 2013).  
 
Considering the current unsatisfactory anti-HBV treatment regimens and the pivotal 
role of anti-viral T cells in HBV control, novel immunotherapeutic strategies for 
revitalizing exhausted and pro-apoptotic T cells are in urgent demand. Since T cells 
are subjected to metabolic stress and closely regulated by cellular interactions in the 
liver sinusoidal microvasculature, potent immunomodulatory mechanisms targeting 
both aspects, such as the NKG2D pathway (Lang et al., 2012; Shafi et al., 2011; Strid 
et al., 2011), could be a promising approach to improve HBV control.  
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3.2 Aim and Hypotheses  
Aim of the study:  
Through study of the NKG2D pathway, we aimed to investigate the role of stress 
surveillance of T cells in the HBV-infected liver.   
 
 
Hypothesis:  
1. We hypothesized that persistent HBV infection may lead to stress molecule 
(NKG2D-L) upregulation on T cells.  
2. We hypothesized that the increased expression of NKG2D-L on T cells may 
render them susceptible to NKG2D-mediated stress surveillance. 
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3.3 Results 
3.3.1 NKG2D-L upregulation on T cells in chronic HBV infection 
The expression of NKG2D ligand (NKG2D-L) is low in healthy tissues, but it can be 
induced by stress, such as infection, inflammation or tumour transformation 
(Champsaur and Lanier, 2010; Raulet et al., 2013). We hypothesised that T cells in 
CHB may upregulate NKG2D-L expression, thereby rendering them susceptible to 
killing by NKG2D+NK cells. To investigate NKG2D-L expression, CD4 and CD8 T 
cells from healthy controls and CHB patients were evaluated by flow cytometry 
using a panel of mAb specific for MICA/B, ULBP1, ULBP2/5/6 (stained with a 
single mAb), and ULBP3. Out of this panel of ligands, MICA/B was increased on T 
cells in CHB patients and further significantly upregulated in those patients with 
ongoing liver inflammation ALT>60 IU/L (Figure 3.1A and B); ULBP1 was also 
selectively elevated on T cells from patients with HBV-related liver inflammation 
(Figure 3.1C). However, significant upregulation of ULBP2/5/6 and ULBP3 on T 
cells in CHB patients was not observed (data not shown; this work credited to Dr. 
Xin-Zi Tang, Maini group 2011).  
To further determine the impact of chronic HBV infection, we next evaluated the T 
cell expression of NKG2D-L within the liver, the site of disease pathology. 
Intrahepatic lymphocytes (IHL) were isolated from surplus liver biopsy tissue and 
compared with matched PBMC samples from CHB patients. IHL of non-HBV 
infected controls isolated either from healthy tissue of liver metastasis resections or 
from transplant perfusates of deceased donor livers were also used for comparison.  
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Figure 3.1 Evaluation of NKG2D ligand expression on T cells from healthy 
controls and CHB patients. (*This work credited to Dr. Xin-Zi Tang, 
2011) 
A Representative plots of ex vivo MICA/B staining of T cells from 
healthy controls, CHB patients with ALT≤60 IU/L, and CHB patients 
with ALT>60 IU/L.  
B Summary results of panel A (HC n=9; CHB (ALT≤60) n=13; CHB 
(ALT>60) n=14; gates set by control isotype staining; analysed by 
Kruskal-Wallis test). 
C Summary results of ex vivo ULBP1 expression of T cells from healthy 
controls, and CHB patients (HC n=11; CHB (ALT≤60) n=16; CHB 
(ALT>60) n=9; analysed by Kruskal-Wallis test).  
 
In ex vivo staining, the proportion of T cells expressing MICA/B was markedly 
increased in the liver compared to the periphery of CHB patients (Figure 3.2A and 
B). Moreover, the MICA/B expression of intrahepatic T cells was considerably 
higher in HBV-infected livers compared to the control livers (Figure 3.2A and B). In 
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this cohort of experiments, preferential enrichment of MICA/B on CD4 T cells in 
both the periphery and liver was also noted (Figure 3.2C and D). 
 
Figure 3.2 Evaluation of NKG2D ligand expression on intrahepatic T cells 
from healthy controls and CHB patients.  
A Representative plots of ex vivo MICA/B staining of paired peripheral 
and intrahepatic T cells from CHB patients, and intrahepatic T cells 
from non-HBV infected control livers. 
B Summary results of panel A (CHB PBMC n=27; CHB IHL n=27; 
Control IHL n=20; black triangles (n=11) indicate intrahepatic 
lymphocytes isolated from healthy part of liver resection tissue; clear 
triangles (n=9) indicate intrahepatic lymphocytes isolated from 
transplant perfusates of deceased donor livers; analysed by 
Kruskal-Wallis test). 
C Comparison summary of MICA/B expression on peripheral CD4 and 
CD8 T cells from CHB patients (n=27; analysed by Wilcoxon signed 
rank test). 
D Comparison summary of MICA/B expression on intrahepatic CD4 and 
CD8 T cells from CHB patients (n=27; analysed by Wilcoxon signed 
rank test). 
  
Since antigen exposure and cellular proliferation can contribute to NKG2D-L 
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viral load, HBeAg status, and T cell proliferation (Ki67+ staining) in CHB patients. 
However, NKG2D-L expression on T cells in our patient cohort did not stratify 
significantly with HBV viral load or HBeAg status (data not shown). In addition, our 
ex vivo findings did not indicate increased proliferation of MICA/B expressing T 
cells than of global T cells (Figure 3.3A and B).   
 
Figure 3.3 Evaluation of proliferation status of MICA/B+ T cells from healthy 
controls and CHB patients.  
A Representative plots of ex vivo Ki67 staining of global (MICA/B-)T 
cells and MICA/B+ T cells from healthy controls and CHB patients. 
B Summary results of panel A (HC n=4; CHB n=10). 
 
For a closer inspection of MICA/B expressing T cells, we applied CD27 and 
CD45RA ex vivo staining to evaluate phenotypic features. In both PBMC and IHL of 
CHB patients, we observed that MICA/B-expressing T cells were composed of 
relatively fewer effector memory (EM) and effector memory revertant (EMRA) 
populations than global T cells (Figure 3.4A-D). Similar to the differentiation pattern 
of TRAIL-R2 positive T cells, MICA/B expressing CD4 and CD8 T cells were 
slightly enriched for naïve or central memory populations respectively (Peppa et al., 
2013).   
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Figure 3.4 Phenotype analysis of MICA/B+ T cells from CHB patients.  
A Representative plots of differentiation status of global (MICA/B-) T 
cells and MICA/B+ T cells from PBMC of CHB patients by ex vivo 
CD27 and CD45RA staining. (Upper right quadrant, lower right 
quadrant, lower left quadrant, and upper left quadrant indicate naïve, 
central memory (CM), effector memory (EM), and effector memory 
re-expressing CD45RA (EMRA) populations, respectively).  
B Summary analysis of panel A (n=10).  
C Representative examples of phenotype analysis of global (MICA/B-) 
and MICA/B+ T cells from IHL of CHB patients by ex vivo CD27 and 
CD45RA staining.  
D Summary analysis of panel C (n=8).  
 
To conclude, our results illustrate that NKG2D ligands are upregulated on T cells in 
CHB, especially in patients with pronounced liver inflammation and on intrahepatic 
T cells. 
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3.3.2 Enrichment of NKG2D-L expression on T cells activated by HBV 
infection 
Although NKG2D ligands were consistently upregulated on T cells from patients 
with CHB, the percentage of expressing cells was low, suggesting that a particular 
subset of T cells was affected. We hypothesised that NKG2D-L might be 
preferentially induced on those T cells activated by HBV infection. By using the 
activation marker HLA-DR, we compared MICA/B expression on activated 
(HLA-DR+) and global (HLA-DR-) T cells. Ex vivo staining of PBMC from patients 
revealed greater enrichment of MICA/B expression on activated T cells (Figure 3.5A 
and B).  
 
Figure 3.5 Evaluation of NKG2D ligand expression on activated T cells from 
CHB patients. 
A Representative plots of ex vivo MICA/B staining of global (HLA-DR-) 
T cells and activated (HLA-DR+) T cells from PBMC of CHB patients.  
B Summary results of panel A (n=22; analysed by Wilcoxon signed rank 
test). 
 
Similarly, the MICA/B upregulation on intrahepatic activated (HLA-DR+) T cells 
was more apparent than on the global (HLA-DR-) fraction (Figure 3.6A and B).  
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Figure 3.6 Evaluation of NKG2D ligand expression on intrahepatic activated T 
cells from CHB patients. 
A Representative plots of ex vivo MICA/B staining of global (HLA-DR-) 
and activated (HLA-DR+) T cells from IHL of CHB patients.  
B Summary results of panel C (n=21; analysed by Wilcoxon signed rank 
test). 
 
Activated T cells in CHB likely consist of a mixture of HBV-specific T cells and 
other bystander T cells. Therefore, we next investigated the NKG2D-L expression on 
HBV-specific T cells identified by anti-viral cytokine, IFN-γ production. Following 
10-day expansion and stimulation with overlapping peptides spanning the HBV core 
protein, we found MICA/B was expressed at much higher levels on HBV-specific 
(IFN-γ+), compared to the global (IFN-γ-), CD4 and CD8 T cells (Figure 3.7A and 
B). 
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Figure 3.7 Evaluation of NKG2D ligand expression on HBV-specific T cells 
from CHB patients 
A. HBV-specific T cells were identified by IFN-γ production following 
short-term expansion and stimulation with overlapping peptides (OLP) 
spanning HBV core protein. Representative plots of MICA/B staining 
of global (IFN-γ-) T cells and HBV-specific (IFN-γ+) T cells.  
B. Summary results of panel A (n=17; analysed by Wilcoxon signed rank 
test). 
 
Probing whether MICA/B was upregulated on HBV-specific T cells, and not just 
secondary to in vitro HBV overlapping peptide (HBV OLP) stimulation, we assessed 
ex vivo HLA-A2/HBV peptide dextramer (HBV Dex) staining. Consistently, the 
results also showed HBV-specific (HBV Dex+) CD8 T cells presented significantly 
higher levels of MICA/B than global (HBV Dex-) T cells (Figure 3.8A and B). 
Furthermore, in a parallel comparison of the same cohort, ex vivo MICA/B 
expression was preferentially enriched on HBV-specific (HBV Dex+) T cells but not 
on CMV-specific (CMV Dex+) T cells (Figure 3.8C). 
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Figure 3.8 Evaluation of NKG2D ligand expression on HBV and CMV-specific 
CD8 T cells from CHB patients. 
A HBV or CMV-specific CD8 T cells were identified by HLA-A2/HBV 
peptide dextramer (HBV Dex) or HLA-A2/NLV-dextramer (CMV Dex) 
staining. Representative plots of ex vivo MICA/B staining on global 
(Dex-) T cells, HBV-specific (HBV Dex+) T cells, and CMV-specific 
(CMV Dex+) T cells (Gates set using control dextramer staining). 
B Summary results of ex vivo MICA/B expression on global (Dex-) T 
cells, HBV-specific (HBV Dex+) T cells (n=19; analysed by Wilcoxon 
signed rank test). 
C Extended comparison and summary of ex vivo MICA/B expression on 
global (Dex-) T cells, HBV-specific (HBV Dex+) T cells, and 
CMV-specific (CMV Dex+) T cells from a subset of the same cohort 
(Global CD8 n=19; HBV Dex+ CD8 n=19; CMV Dex+ CD8 n=9; 
analysed by Kruskal-Wallis test). 
 
To examine whether intrahepatic HBV-specific T cells can also upregulate 
NKG2D-L expression, lymphocytes obtained from the livers of CHB patients were 
stimulated with HBV OLP overnight. Similar to the periphery, MICA/B levels were 
considerably higher on intrahepatic HBV-specific (IFN-γ+) CD4 and CD8 T cells 
than on global (IFN-γ-) T cell fractions (Figure 3.9A and B). In parallel, MICA/B 
levels were noted to be further enriched on intrahepatic HBV-specific T cells than 
those from matched peripheral blood samples (Figure 3.9C).  
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Figure 3.9 Evaluation of NKG2D ligand expression on intrahepatic 
HBV-specific T cells from CHB patients. 
A. Intrahepatic HBV-specific T cells were identified by IFN-γ production 
following overnight stimulation with OLP spanning HBV core protein. 
Representative plots of MICA/B staining of intrahepatic global (IFN-γ-) 
T cells and intrahepatic HBV-specific (IFN-γ+) T cells. 
B. Summary results of panel A (n=12; analysed by Wilcoxon signed rank 
test). 
C. Summary results of MICA/B expression on HBV-specific (IFN-γ+) T 
cells from paired PBMC and IHL following overnight stimulation with 
OLP spanning HBV core protein (n=10; analysed by Wilcoxon rank 
test). 
 
Notably, in the HBV-infected liver, both activated (HLA-DR+) and HBV-specific 
(IFN-γ+) CD4 T cells showed markedly higher MICA/B than their CD8 counterparts 
(Figure 3.10A and B). 
In conclusion, our study demonstrates for the first time that NKG2D-L can be 
expressed by non-virally infected human T cells and are preferentially enriched on 
activated and HBV-specific T cells.  
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Figure 3.10  Comparison of NKG2D ligand expression on intrahepatic CD4 and 
CD8 T cells within activated and HBV-specific subsets. 
A Comparison summary of ex vivo MICA/B expression on activated 
(HLA-DR+) CD4 and CD8 T cells from IHL of CHB patients (n=21; 
analysed by Wilcoxon rank test). 
B Comparison summary of MICA/B expression on intrahepatic 
HBV-specific (IFN-γ+) CD4 and CD8 T cells following overnight 
stimulation with OLP spanning HBV core protein (n=12; analysed by 
Wilcoxon rank test). 
 
3.3.3 Oxidative stress in CHB as an underlying mechanism of NKG2D-L 
induction on T cells 
NKG2D-L expression is tightly regulated and normally rare on healthy cells. 
However, in response to various stimuli or cellular stress, such as virus infection, 
genotoxic or oxidative stress, these "stress ligands" can be upregulated to initiate 
corresponding immune interactions (Champsaur and Lanier, 2010; Rabinovich et al., 
2000; Raulet et al., 2013; Zingoni et al., 2012). In CHB, persistent HBV infection 
and chronic liver inflammation can cause continuing antigenic stimulation and 
pathogenic oxidative stress (Hagen et al., 1994; Shimoda et al., 1994). Therefore, we 
investigated whether in vitro Ag-induced TCR signalling or oxidative stress could 
contribute to T cell NKG2D-L upregulation. We used plate-bound αCD3 antibody 
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1991; Ledbetter et al., 1985; Martin et al., 1986). Additionally, hydrogen peroxide 
(H2O2), a cellular metabolic product of physiological reactive oxygen species (ROS) 
(Nathan and Cunningham-Bussel, 2013; Valko et al., 2007) was also applied for 
oxidative stress stimulation. Purified CD4 T cells isolated from healthy donors or 
CHB patients were either rested or treated with plate-bound αCD3 antibody for 48 
hours and/or 1mM H2O2 for 1 hour. In this exploratory study, we found striking 
MICA/B upregulation, analogous to that seen on intrahepatic T cells, following H2O2 
treatment; by contrast, αCD3 stimulation did not significantly induce MICA/B either 
alone or in combination with H2O2 (Figure 3.11A and B). Similarly, no significant 
MICA/B induction was observed in experiments using either αCD3/αCD28 for full T 
cell activation or αCD28/PMA treatment for signalling activation bypassing the 
TCR/CD3 complex (Molinero et al., 2002) (data not shown). Throughout 
preliminary screenings, other relevant stimuli were also tested for T cell MICA/B 
induction in control PBMC, including IFN-α, TNF-α, IL-2, IL-10, IL-15, IL-17, EGF, 
as well as ER stress inducer thapsigargin, but without positive results (data not 
shown). Although slight upregulation of MICA/B on T cells was observed upon 
IFN-α stimulation (500IU/ml for 4 hours), it failed to reproduce intrahepatic 
expression on peripheral T cells (data not shown).    
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Figure 3.11 Evaluation of NKG2D ligand induction on purified CD4 T cells 
upon TCR signalling or oxidative stress stimulation. 
A Purified CD4 T cells from a healthy donor were treated with 
plate-bound anti-CD3 (0.5µg/ml) or rested for 48hr and/or stimulated 
1-hour with 1mM H2O2. Representative plots show the changes of 
MICA/B expression on purified CD4 T cells following different in vitro 
stimuli.   
B Purified CD4 T cells from a CHB patient were treated with plate-bound 
anti-CD3 (0.5µg/ml) or rested for 48hr and/or stimulated 1-hour with 
1mM H2O2. Representative plots show the changes of MICA/B 
expression on the purified CD4 T cells following different in vitro 
stimuli. 
 
We then examined the time-course and dose-response of H2O2 induction of MICA/B. 
As before, purified CD4 T cells isolated from healthy individuals were in resting 
incubation for 48 hours to minimise other unwanted interactions. In the final 2.0, 1.0, 
or 0.5 hours, oxidative stress was induced by the addition of varying concentrations 
of H2O2. From this, we concluded that 1-hour stimulation with 0.5mM H2O2 
optimally induced MICA/B expression on CD4 T cells from healthy individuals 
(Figure 3.12A and B). We then tested purified CD4 T cells from 14 healthy donors 
with the same 1hr stimulation at 0.5mM H2O2, finding a striking and consistent 
induction of MICA/B in all donors, with a mean increase of 5-fold (Figure 3.12 C).               
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Figure 3.12 Evaluation of NKG2D ligand induction upon oxidative stress 
stimulation of purified CD4 T cells. 
A Purified CD4 T cells isolated from healthy individuals were treated 
with H2O2 for different durations and at different concentrations. 
Representative plots show the MICA/B changes from untreated CD4 T 
cells (baseline) to those with short-term H2O2 treatment at 2.0, 1.0, and 
0.5 hours. 
B Summary results of panel A (n=2). 
C Summary of MICA/B expression on untreated CD4 T cells compared 
to those with 1-hour 0.5mM H2O2 treatment (n=14; analysed by 
Wilcoxon signed rank test). 
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counter-regulatory pathways in whole PBMC to diminish NKG2D-L expressing T 
cells; these findings are compatible with the possibility that NKG2D-L-expressing T 
cells are preferentially deleted in the presence of NK cells within PBMC cultures 
(Figure 3.13A-D).   
 
Figure 3.13 Evaluation of NKG2D-L induction on T cells upon oxidative stress 
stimulation. 
A Parallel comparison of H2O2 effects on T cell MICA/B induction in 
isolated CD4 T cells and in whole PBMC (UT: untreated; n=6; 
analysed by Wilcoxon signed rank test). 
B Parallel comparison of H2O2 effects on T cell ULBP1 induction in 
isolated CD4 T cells and in whole PBMC (UT: untreated; n=6; 
analysed by Wilcoxon signed rank test). 
C Parallel comparison of H2O2 effects on T cell ULBP2/5/6 induction in 
isolated CD4 T cells and in whole PBMC (UT: untreated; n=6; 
analysed by Wilcoxon signed rank test). 
D Parallel comparison of H2O2 effects on T cell ULBP3 induction in 
isolated CD4 T cells and in whole PBMC (UT: untreated; n=6; 
analysed by Wilcoxon signed rank test). 
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To explore additional possible co-regulatory pathways for limiting NKG2D-L 
expressing T cells upon oxidative stress, we assessed the co-expression of death 
receptors (Fas/CD95 and TRAIL-R2) and the exhaustion marker PD-1 on isolated 
MICA/B expressing CD4 T cells in parallel experiments. Extended H2O2 stimulation 
experiments revealed that both Fas and PD-1 were preferentially increased on 
MICA/B expressing CD4 T cells, though no significant changes on TRAIL-R2 levels 
were noted (Figure 3.14A-C and data not shown). These findings suggest oxidative 
stress has the ability to manipulate T cell Fas and PD-1 in addition to NKG2D-L.  
 
 
Figure 3.14 Evaluation of upregulation of death receptor (Fas) and exhaustion 
marker (PD-1) on NKG2D-L expressing CD4 T cells upon oxidative 
stress stimulation. 
A Purified CD4 T cells isolated from healthy individuals were rested for 
48hr and treated in the final hour with 0.5mM H2O2. Representative 
plots of co-expression of Fas or PD-1 on MICA/B expressing CD4 T 
cells.  
B Summary results of Fas expression on MICA/B+CD4 T cells upon 
oxidative stimulation (n=6; analysed by Wilcoxon signed rank test). 
C Summary results of PD-1 expression on MICA/B+CD4 T cells upon 
oxidative stimulation (n=6; analysed by Wilcoxon signed rank test). 
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In conclusion, our results indicate that oxidative stress could be a factor driving 
NKG2D-L upregulation on T cells, rendering stressed T cells susceptible to immune 
regulation in CHB. 
 
3.3.4 Restoration of activated or HBV-specific T cells upon NKG2D blockade 
or NK cell depletion 
We postulated that the expression of NKG2D-L by T cells in CHB would render 
them susceptible to engagement with NKG2D-expressing NK cells, triggering their 
deletion. Although this process was likely to have already been engaged in vivo in 
the HBV-infected liver and therefore not easily interrupted in vitro, we tested 
whether any T cell responses could still be rescued by in vitro blockade. To probe the 
impact of the NKG2D pathway and NK cells on activated and HBV-specific T cells, 
we therefore performed NKG2D blockade and NK cell depletion by using NKG2D 
blocking mAb and NK cell isolation kits, respectively. PBMC of CHB patients were 
cultured short-term (10 days) with overlapping peptides (OLP) spanning HBV core 
protein and activated T cells were identified by HLA-DR staining. Following NK 
cell depletion, significant restoration of activated CD4 and CD8 T cells was noticed. 
However, only partial rescue of activated T cells was observed upon NKG2D 
blockade (Figure 3.15A and B), in line with our previous work indicating that other 
pathways such as TRAIL are involved in NK cell killing of activated T cells (Peppa 
et al., 2013). 
 
  
 
82 
 
Figure 3.15 Evaluation of the impact of NKG2D pathway and NK cells on 
activated T cells in CHB.  
A Following short-term culture with overlapping peptides spanning HBV 
core protein, the percentage of activated (HLA-DR+) T cells was 
evaluated from PBMC (baseline), PBMC with NKG2D blockade by 
anti-NKG2D mAb, and PBMC with NK cells depleted by NK cell 
isolation kits. Representative plots of activated (HLA-DR+) T cell 
restoration upon NKG2D blockade and NK cell depletion.  
B Summary results of panel A, showing percentage restoration after 
subtraction of baseline (n=8; analysed by Wilcoxon rank test).  
 
In the same culture setting, we proceeded to evaluate the effects of NKG2D blockade 
and NK cell depletion on HBV-specific T cells. PBMC isolated from CHB patients 
were cultured short-term (10 days) with HBV OLP, and HBV-specific T cells were 
identified by IFN-γ production. Following NK cell depletion and NKG2D blockade, 
restoration of HBV-specific CD4 T cells by both methods was observed in patients 
with ongoing liver inflammation (ALT>60 IU/L), but not in patients with ALT≤60 
IU/L (Figure 3.16A-C). In addition, the rescue effect upon NK cell depletion was 
suppressed by re-adding NK cells at a physiological ratio in the beginning of the 
short-term culture (Figure 3.16A and B). 
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Figure 3.16 Evaluation of the impact of NKG2D pathway and NK cells on 
HBV-specific T cells in CHB.  
A Following short-term culture with overlapping peptides (OLP) 
spanning HBV core protein, the percentage of HBV-specific (IFN-γ+) 
CD4 T cells was evaluated from PBMC, PBMC with NKG2D blockade, 
PBMC with NK cell depletion (ΔNK), and NK cell-depleted PBMC 
with NK cells re-added. Representative plots of HBV-specific (IFN-γ+) 
CD4 T cell changes upon NKG2D blockade, NK cell depletion, and 
NK cell re-adding. 
B Summary results of panel A from patients with ALT>60 IU/L (n=15; 
percentage is after subtraction of baseline IFN-γ production without 
OLP stimulation; analysed by Friedman test). 
C Extended comparison of HBV-specific (IFN-γ+) CD4 T cell restoration 
upon NKG2D blockade in patients with ALT≤60 IU/L and patients 
with ALT>60 IU/L (ALT≤60 n=11; ALT>60 n=15; analysed by 
Wilcoxon signed rank test).  
D Extended comparison of HBV-specific (IFN-γ+) CD4 T cell restoration 
upon NKG2D blockade between PBMC and NK cell-depleted PBMC 
(ΔNK) from patients with ALT>60 IU/L (PBMC n=15; NK 
cell-depleted PBMC n=13; percentage is after subtraction of baseline 
IFN-γ production without OLP stimulation; analysed by Mann Whitney 
test). 
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Since the NKG2D receptor is also found on other cells, such as NKT cells, γδ T cells, 
and activated CD8 T cells (Eagle and Trowsdale, 2007), we examined NKG2D 
blockade effects on NK cell-depleted PBMC in our parallel panel simultaneously. 
Notably, rescue of HBV-specific T cells was not seen upon NKG2D blockade in the 
absence of NK cells, implying an NK cell-dependent NKG2D effect (Figure 3.16D).  
Consistent with the enhancement of peripheral anti-viral responses upon NKG2D 
blockade, intrahepatic HBV-specific CD4 T cells, but not CD8, were also 
significantly restored by blocking the NKG2D pathway following overnight HBV 
OLP stimulation (Figure 3.17A and B).  
 
 
Figure 3.17 Evaluation of the impact of NKG2D pathway on intrahepatic 
HBV-specific T cells in CHB. 
A Following overnight stimulation with overlapping peptides (OLP) 
spanning HBV core protein, the percentage of intrahepatic 
HBV-specific (IFN-γ+) T cells was evaluated from intrahepatic 
lymphocytes (IHL), and IHL with NKG2D blockade. Representative 
plots of intrahepatic HBV-specific (IFN-γ+) T cell restoration upon 
NKG2D blockade. 
B Summary results of panel A (n=12; analysed by Wilcoxon signed rank 
test). 
C Comparison summary of HBV-specific (IFN-γ+) CD4 T cell restoration 
upon NKG2D blockade from paired PBMC and IHL following 
overnight HBV OLP stimulation (n=9; analysed by Wilcoxon signed 
rank test). 
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When comparisons were made between intrahepatic lymphocytes and paired 
peripheral lymphocytes in parallel, our experiments demonstrated NKG2D blockade 
preferentially rescued HBV-specific CD4 T cells in the liver rather than the 
periphery (Figure 3.17C). 
Taken together, these results indicate that NK cells have suppressive effects on 
activated and HBV-specific T cells. Furthermore, HBV-specific CD4 T cells, 
particularly the intrahepatic fraction, are susceptible to NK cell dependent NKG2D 
killing in the setting of active CHB, resulting in constraints on antiviral immunity. 
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3.4 Conclusions and Discussion   
Antiviral T cells are crucial in immune control of HBV (Maini et al., 2000; Thimme 
et al., 2003); however, many intrinsic and extrinsic factors have been discovered to 
cause T cell functional exhaustion in patients with CHB (Maini and Schurich, 2010; 
Protzer et al., 2012). Upregulation of pro-apoptotic protein Bcl2-interacting mediator 
(Bim) also drives susceptibility of HBV-specific T cells to profound apoptotic 
deletion (Lopes et al., 2008). Therefore, an important consideration in improving 
current HBV therapy is to thoroughly define the potential negative impacts on 
anti-viral T cells. 
 
In humans, eight NKG2D ligands including MICA/B and ULBP1-6 have been 
identified so far (Champsaur and Lanier, 2010; Raulet et al., 2013). Due to the 
normally rare but inducible expression upon various types of cellular stress, these 
ligands constitute part of the lymphoid stress-surveillance (LSS) system (Shafi et al., 
2011; Strid et al., 2011). Moreover, the fine-tuned and diverse expression of the 
NKG2D-L with their highly polymorphic character limits tumour or virus evasion 
underscoring their non-redundant immune significance (Cosman et al., 2001; Eagle 
and Trowsdale, 2007; Gonzalez et al., 2008; Mistry and O'Callaghan, 2007). Firstly, 
our ex vivo study clearly demonstrated that human T cells are capable of expressing 
selective NKG2D-L. This is the first time, to our knowledge, that non-virally 
infected human T cells have been found to express NKG2D-L directly ex vivo.  
Previous virus research has shown that NKG2D-L can be delicately adjusted at 
multiple transcriptional and post-transcriptional levels to intricately regulate their 
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expression on certain cell populations, such as stromal cells (Fielding et al., 2014; 
Lam et al., 2013; Norman et al., 2011; Raulet et al., 2013; Richard et al., 2010). 
Likewise, the disproportionate upregulation of NKG2D-L on activated and 
HBV-specific T cells pointed to differential regulation. In CHB, T cells susceptible 
to TRAIL-mediated NK cell killing in common with MICA/B positive T cells, 
showed a less senescent or terminal differentiated phenotype, comprised largely of 
naïve and central memory cells (Peppa et al., 2013). Unlike CMV-specific T cells, 
HBV-specific T cells, with profoundly exhausted and apoptotic qualities, also show 
striking induction of NKG2D-L and TRAIL-R2, and are sensitive to NKG2D and 
TRAIL mediated depletion (Peppa et al., 2013). Taken together, these findings 
indicate that chronic HBV infection can mold T cells to present multiple features 
making them vulnerable to immune regulation. 
 
To investigate the underlying mechanisms of NKG2D-L upregulation on T cells, we 
first stratified our patient cohort by different virological and clinical parameters. In 
contrast to the preferential enrichment of NKG2D-L expression on T cells from 
patients with pronounced liver inflammation (ALT>60 IU/L), the link between T cell 
NKG2D-L upregulation with either HBeAg or viral load did not appear statistically 
significant. In view of the considerably higher levels of NKG2D-L expression on 
intrahepatic T cells, we next considered various factors relevant to HBV-related liver 
inflammation. Although our ex vivo and in vitro studies were unable to support 
antigen-driven activation and proliferation as a trigger for T cell NKG2D-L 
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induction, they did reveal that oxidative stress can strikingly upregulate NKG2D-L 
expression of peripheral T cells, achieving the levels seen in the HBV-infected liver.   
 
Reactive oxygen species (ROS), such as superoxide anion, hydroxyl radical, and 
hydrogen peroxide, are products of cellular metabolism as well as important 
signalling molecules with broad biological effects (Fridovich, 1999; Nathan and 
Cunningham-Bussel, 2013; Nordberg and Arner, 2001). Recent advances in such 
redox mechanisms have demonstrated that ROS can regulate T cell function, 
differentiation, and survival by modulating several transcription factors and 
mitogen-activated protein kinases, including p53, nuclear factor κB (NFκB), nuclear 
factor erythroid-2-related factor 2 (Nrf2), extracellular signal-regulated kinase (ERK) 
pathway, and p38-MAPK pathway (Devadas et al., 2002; Kesarwani et al., 2013; 
Kim et al., 2008a; Kim et al., 2008b; Polyak et al., 1997; Suzuki et al., 1997; 
Trachootham et al., 2008). Moreover, imbalance of cellular redox state and oxidative 
stress caused by inappropriate accumulation of ROS have been implicated in aging, 
genetic damage, infection, inflammation and carcinogenesis (Nathan and 
Cunningham-Bussel, 2013; Reuter et al., 2010; Valko et al., 2007). Substantial 
evidence has shown that oxidative stress, resulting from persistent viral infection 
(Higgs et al., 2014; Schwarz, 1996; Severi et al., 2006) and chronic inflammation 
(Jaeschke, 2011; Mittal et al., 2014; Reuter et al., 2010), is increased in CHB patients 
and even more prominent within the liver, the origin of HBV pathology (Bolukbas et 
al., 2005; Fujita et al., 2008; Hagen et al., 1994; Li et al., 2015; Shimoda et al., 1994). 
Hydrogen peroxide, a relatively weak endogenous ROS being widely used for 
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oxidative stress induction, has physiological significance including the capability of 
diffusing through biological membranes and as an intermediate in generating other 
more reactive oxidizing products (Fridovich, 1997; Massey, 1994; Robbins and Zhao, 
2004; Winterbourn et al., 2000). Currently, cellular production of hydrogen peroxide 
has been regarded as a damage signal of tissue injury and inflammation (van der 
Vliet and Janssen-Heininger, 2014; Wittmann et al., 2012), since it contributes to 
Ca2+ influx and ATP release along with various signalling cascades, such as ERK 
and NFκB pathway activation as well as IL-2/IL-2Rα expression (Devadas et al., 
2002; Kesarwani et al., 2013; Los et al., 1995). Thus, by using hydrogen peroxide in 
vitro, we demonstrated that oxidative stress could be an underlying mechanism of 
NKG2D-L induction on T cells in CHB (Allegretti et al., 2013; Borchers et al., 2006; 
Rabinovich et al., 2000). Moreover, we observed that the heterogeneous NKG2D-L 
responses to oxidative stress were similar to the ex vivo pattern of selectively 
upregulated MICA/B and ULBP1 on T cells in CHB patients. In agreement with 
previous documented research showing a positive association between oxidative 
stress and the severity of HBV-related liver disease (Bolukbas et al., 2005; Duygu et 
al., 2012; Fujita et al., 2008; Kitada et al., 2001), our study demonstrated higher 
upregulation of NKG2D-L on T cells from patients with greater liver injury (ALT > 
60 IU/L). On a background of aberrant oxidative stress, all newly generated cells 
encountering their antigen in the liver might be expected to be affected, which could 
explain the detection of NKG2D-L expressing T cells in our patient cohort. However, 
the discrepancy of NKG2D-L upregulation between whole PBMC and isolated CD4 
T cells in vitro suggests NKG2D-L expressing T cells are tightly constrained and that 
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counter-regulatory pathways may also be initiated by oxidative stress. Besides a 
broad spectrum of immune responses, oxidative stress and cellular redox changes can 
trigger many cellular interactions, such as perforin-mediated and 
DNAM-1-dependent NK cell killing, to regulate T cell function and survival 
(Ardolino et al., 2011; Kesarwani et al., 2013; Rabinovich et al., 2000). Therefore, 
the selective NKG2D-L expression on T cells in CHB could be viewed as a highly 
orchestrated phenomenon, reflecting complex immune networks. 
 
Within the chronically HBV-infected and inflamed liver, T cells are directly exposed 
not only to overwhelming HBV antigenic stimulation, but also to other cellular and 
metabolic stressors (Guidotti et al., 2015b; Protzer et al., 2012). Consistent with our 
results illustrating more marked upregulation of NKG2D-L in the liver than the 
periphery, pathogenic NK cell responses, arginase-producing myeloid cells causing 
L-arginine deprivation, and oxidative stress are all more prominent within the 
HBV-infected liver (Hagen et al., 1994; Pallett et al., 2015; Peppa et al., 2013). In 
line with greater HBV-specific T cell restoration upon NKG2D blockade in the liver 
compared to the periphery, we suggest that the NKG2D pathway is more influential 
in the HBV-infected liver, especially in the presence of ongoing inflammation.  
 
Similar to the preferential NKG2D-L upregulation on CD4 T cells in other chronic 
viral infections (Schuster et al., 2014), our study also demonstrated CD4 T cells 
expressed higher MICA/B than their CD8 counterparts, particularly the activated and 
HBV-specific fractions within the HBV-infected liver. As a part of the complicated 
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NKG2D-L control system, the epidermal growth factor receptor (EGFR) signalling 
pathway can stabilize the cellular NKG2D-L expression and further shape the 
immunological visibility of cells (Vantourout et al., 2014). Our findings of 
NKG2D-L upregulation in chronic HBV infection are consistent with previous 
studies suggesting prominent activation of the EGFR pathway in CHB patients 
(Barreiros et al., 2009). However, unlike CD4 T cells, CD8 T cells have very 
low/undetectable EGFR, the receptor for EGF (Dai et al., 2014; Zaiss et al., 2013). 
This could possibly account for why we find that CD8 T cells have less capability to 
maintain NKG2D-L expression and explain the preferential enrichment of 
NKG2D-L on CD4 T cells. In addition, unlike CD4 T cells, CD8 T cells usually 
possess NKG2D (Eagle and Trowsdale, 2007). Very little is known about possible 
pathophysiological interactions between NKG2D-L and NKG2D expressed on the 
same cells. The possibility of either direct self-activation or ligand-internalization on 
CD8 T cells might also account for the reduced NKG2D-L displayed on CD8 T cells 
in our study.   
 
The preferential susceptibility of CD4 T cells to NK cell interactions may have 
specific implications in viral immunity (Rehermann, 2013; Rydyznski et al., 2015; 
Schuster et al., 2014; Waggoner et al., 2012; Waggoner and Kumar, 2012). Sufficient 
anti-viral CD8 T cell responses together with neutralizing antibody development 
crucial for the outcome of HBV infection both depend on adequate CD4 T cell help 
(Chisari and Ferrari, 1995; Guidotti et al., 2015b). As previous research in murine 
viral models demonstrated, since CD8 T cells express higher CD48 that can engage 
  
 
92 
the inhibitory receptor CD244 on NK cells, CD4 T cells are predominant targets for 
NK cell killing (Crome et al., 2013; Rehermann, 2013; Waggoner et al., 2012; 
Waggoner and Kumar, 2012). The seminal mouse LCMV study from Waggoner et al. 
demonstrated that NK cells serve as rheostats of disease activity in different viral 
load settings by primarily eliminating activated CD4 T cells and subsequently 
hindering CD8 T cell immunity (Waggoner et al., 2012). Our findings of NKG2D-L 
expression and rescue of antiviral immunity by NKG2D blockade in active CHB 
patients, suggest that NKG2D-mediated interactions may serve as a homeostatic 
response for surveillance of stressed cells, thereby collaterally constraining adaptive 
immunity in chronic HBV infection.   
 
Despite the clear-cut upregulation of NKG2D-L on T cells in chronic HBV infection, 
dramatic restoration of antiviral immunity upon NKG2D blockade was not observed. 
This may be due to the following reasons. First, in the pathogenic and inflammatory 
milieu, many inhibitory or apoptotic molecules and regulatory interactions may be 
triggered (Kesarwani et al., 2013; Maini and Schurich, 2010; Protzer et al., 2012; 
Rabinovich et al., 2000). Corresponding to our findings, as a pathological signature 
of chronic hepatitis B (Ha et al., 2010; Hagen et al., 1994; Poli, 2000), oxidative 
stress can induce both PD-1 and Fas expression on NKG2D-L expressing T cells. 
Therefore, the majority of highly activated and stressed T cells may be depleted or 
prone to apoptosis, leaving few of them amenable to rescue following in vitro 
NKG2D blockade. Second, other pathways may also participate in NK cell-mediated 
deletion. Indeed, the chronic HBV-infected and inflamed liver is favorable for 
  
 
93 
DNAM-1 and TRAIL-dependent NK cell regulation (Ardolino et al., 2011; Schuster 
et al., 2014). According to previous HBV research on the TRAIL pathway, despite 
significant rescue of HBV-specific T cells following TRAIL-R blockade, the 
recovery was incomplete (Peppa et al., 2013). For the optimized restoration of 
antiviral immunity, dissecting all possible regulatory mechanisms could be a 
worthwhile pursuit. Since many pathways have synergistic effects and are required to 
fully activate NK cells, it is possible that the NKG2D pathway not only can drive 
activation and cytotoxicity of NK cells, but also synergise killing ability through 
other pathways (Bryceson et al., 2006b). Unlike the TRAIL pathway whose effector 
function can be terminated by TRAIL pathway blockade, the degranulation 
cytotoxicity triggered by NKG2D-L is unable to be fully abolished once the NKG2D 
receptor is engaged. As a result, when the killing cascade is initiated, NK cell 
mediated deletion cannot be fully reversed by NKG2D blockade alone. Furthermore, 
the highly polymorphic NKG2D-L have unique functional heterogeneity and may 
engage with an undefined receptor on T cells other than NKG2D to suppress T cell 
proliferation (Kriegeskorte et al., 2005; Raulet et al., 2013). Thus, further 
investigating all aspects of the NKG2D pathway may provide a better understanding 
of T cell survival in CHB. Overall, we would anticipate that in vivo NKG2D 
blockade would rescue substantially greater HBV-specific T cells than what was 
achievable in vitro. However, it is also likely that this pathway is merely a small 
portion of the pathological regulatory mechanisms in CHB pathology and therefore 
not sufficient to fully decode the complexity of this immune network.  
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To conclude, these key points sum up our research. First of all, our study clearly 
demonstrated in chronic HBV infection, T cells, especially the intrahepatic and 
HBV-specific fractions, upregulate selective NKG2D-L, allowing them to engage in 
NKG2D-dependent NK cell regulation. Additionally, the NKG2D-L expression 
pattern of T cells can be recapitulated by oxidative stress, a feature of HBV 
pathology. This implies that in the HBV-infected and inflamed liver, 
NKG2D-dependent T cell/NK cell interactions may serve as a homeostatic response 
for stress surveillance, resulting in constraints on antiviral immunity. Therefore, to 
further optimize antiviral responses and improve HBV therapy, efforts to minimize 
HBV-related oxidative stress should be considered.  
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Chapter 4 NKG2D-mediated NK cell Regulation in Chronic 
HBV Infection 
4.1 Introduction: NK cell-mediated T cell regulation and the 
immunopathology implications in virus disease 
NK cells are an important cellular component of innate immunity. The conventional 
view was that NK cells directly participate in the first-line defence against viral 
infection and provide support for adaptive immunity to achieve viral control. 
However, there is growing recognition that NK cells can also act as regulatory cells 
to restrain T cell anti-viral immunity. In fact, NK cells have the potential to diversely 
modulate T cell responses in autoimmune disease or transplantation settings, as well 
as regulating pathological sequelae in viral infection (Crome et al., 2013).  
 
In CHB, inadequate priming support from intrahepatic antigen-presenting cells (APC) 
may be a key driver of T cell exhaustion and hypo-responsiveness (Isogawa et al., 
2005; Maini and Schurich, 2010). Recent research demonstrates the ability of NK 
cells to modulate APC function and interfere with adaptive immunity against various 
pathogens (Crome et al., 2013; Sun and Lanier, 2011). In one MCMV study, NK 
cells have been reported to hinder anti-viral T cell responses by limiting the 
effectiveness of APC priming for T cells in a perforin-mediated manner (Andrews et 
al., 2010). Moreover, the augmentation of antigen presentation efficacy following 
NK cell depletion in LCMV-infected mice also suggests NK cell-mediated APC 
modulation could be an influential mechanism to alter anti-viral T cell immunity (Su 
et al., 2001).  
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One mechanism by which NK cells can regulate T cells is cytokine production. For 
example, previous murine research has shown, in response to MCMV infection, NK 
cells can suppress CD8 T cells by secreting the immunosuppressive cytokine, IL-10. 
The subsequent enhancement of T cell anti-viral immunity upon either diminishing 
IL-10 from NK cells or directly neutralizing IL-10 further validated the 
unappreciated immune restraints from the NK cell-mediated cytokine milieu (Lee et 
al., 2009).  
 
Apart from cytokine production and APC priming modulation, NK cells can directly 
kill CD4 and CD8 T cells to suppress adaptive immunity. In CHB, NK cells can 
exert TRAIL-mediated killing not only of HBV-infected hepatocytes, but also of 
HBV-specific CD8 T cells (Dunn et al., 2007; Peppa et al., 2013). The significant 
restoration of HBV-specific CD8 T cells achieved by NK cell depletion, TRAIL or 
TRAIL-R2 blockade, demonstrated that TRAIL-dependent NK cell killing adversely 
impaired adaptive immunity in CHB (Peppa et al., 2013). Besides human HBV 
studies, in MCMV models, activated CD4 T cell killing by TRAIL positive NK cells 
was also reported to constrain viral-induced autoimmunity (Schuster et al., 2014). 
Taken together, these findings implicate the TRAIL pathway as a potent effector arm 
of NK cells which can significantly affect T cell immunity and tissue pathology.  
 
In patients with chronic HBV infection, the receptor 2B4/CD244 has been reported 
to be one driver of exhaustion, which inhibits the proliferation and cytotoxicity of 
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HBV-specific T cells in the periphery and liver (Raziorrouh et al., 2010). Likewise, 
in mouse LCMV models, 2B4 is considered as an inhibitory molecule not only 
participating in CD8 T cell exhaustion (Blackburn et al., 2009; Wherry et al., 2007), 
but also providing self-tolerant signalling for NK cells (Waggoner et al., 2010). 
When mice lacking 2B4 were infected with LCMV, 2B4-deficient NK cells caused 
long-lasting pathology and the consequent virus persistence. Moreover, deletion of 
activated CD8 T cells by NK cells also developed in either 2B4-deficient NK cell or 
CD48-KO T cell settings (Waggoner et al., 2010). Overall, these findings indicate 
that an imbalanced interaction between 2B4 and CD48 can disturb innate and 
adaptive immunity in viral infection disease.  
 
As a part of the lymphoid stress surveillance system, NKG2D-positive NK cells can 
promptly respond to stress-induced ligands in various pathologic situations, such as 
infection, inflammation and tumour transformation (Eagle and Trowsdale, 2007; 
Shafi et al., 2011). In LCMV infected mice, NK cells with upregulated NKG2D were 
shown to directly kill CD8 T cells by NKG2D-mediated perforin lysis. After NK cell 
depletion or NKG2D blockade, the subsequent improvement of T cell immunity and 
rapid virus control both confirmed the negative impact of NKG2D-dependent 
regulation (Lang et al., 2012). Moreover, recent in vitro studies also discovered that 
the NKG2D pathway is responsible for NK cell killing of activated human CD4 T 
cells (Cerboni et al., 2007b; Nielsen et al., 2012).  
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Taking these discoveries into account, we can conclude that NK cells not only 
contribute to first-line defence against virus infection, but also have regulatory 
functions to modulate adaptive anti-viral immunity. Through impairing APC priming, 
releasing immunosuppressive cytokines or direct killing of T cells, NK cells can 
compromise T cell immunity and potentially lead towards viral chronicity. On the 
other hand, NK cell-meditated T cell regulation may have protective homeostatic 
value. Viral infection, in some cases, can arouse T cell-mediated autoimmune 
responses to exacerbate disease progression (Getts et al., 2013; McKinney et al., 
2015). Such self-destructive reactions have been revealed to cause tissue pathology, 
vital organ damage, and even lethal consequences (Getts et al., 2013). Thus, NK cells 
may serve as an important homeostatic control to inhibit T cell-mediated 
autoimmunity at the expense of antiviral immunity and viral persistence (Schuster et 
al., 2014).  
 
In another aspect, NK cells can act as rheostats of disease activity by modulating T 
cell immunity. Specifically, Waggoner et al. showed that in the face of 
overwhelming virus infection, NK cell killing of CD4 T cells caused the subsequent 
anti-viral CD8 T cell exhaustion and LCMV chronicity. Nevertheless, in this case, 
the NK cell cytotoxicity was regarded as protective to host survival, since the 
vigorous but harmful T cell responses in the absence of NK cell suppression 
eventually led to extensive tissue damage and host death (Waggoner et al., 2012). 
Together, these results suggest that in certain instances of viral infection, while 
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determining host homeostasis or devastating complications, T cells could become 
expendable sacrifices of NK cell regulation.  
 
To conclude, recent research has demonstrated NK cell-mediated T cell regulation 
has multiple facets in viral infection. Whether the effects are direct or indirect, 
harmful or protective, they all display the complexity of the immune networking 
system. Here, we chose to focus our study on the NKG2D pathway, postulating that 
within the HBV-infected liver, it constitutes an important part of NK cell immune 
communication as well as stress surveillance. Therefore, by investigating NK cell 
responses and exploring cross talk with T cells through the NKG2D axis, we aimed 
to shed light on a new aspect of HBV immunology of potential relevance for 
therapies to combat this infection. 
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4.2 Aim and Hypotheses 
Aim of the study:  
Through study of the NKG2D pathway, we aimed to investigate the potential driving 
forces for pathogenic immunoregulation of NK cells in CHB.  
 
 
Hypothesis:  
1. We hypothesized that NKG2D-L expressing cells could activate cytotoxicity of 
NK cells in CHB. 
2. We hypothesized that the potent immunomodulatory cytokine, IFN-α may 
augment NK cell regulation via the NKG2D pathway.  
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4.3 Results 
4.3.1 NK cell activation, degranulation, and cytokine production driven by 
NKG2D-L expressing cells  
In the previous chapter, our results showed that T cells upregulate NKG2D-L in 
CHB. We postulated that this would allow them to engage the NKG2D receptor on 
NK cells and drive NK cytotoxicity. To assess the impact of NKG2D engagement of 
NK cells from patients with CHB, we employed a B-lymphoblastoid cell line 
transfected with MICA*008 (C1R-MICA) as our target cells (kindly provided by 
Antoine Toubert, INSERM). A control cell line lacking MICA (C1R) served as a 
comparison (Chauveau et al., 2014; Tieng et al., 2002). Isolated NK cells from CHB 
patients were co-cultured with target cells at 1:1 ratio for 6 hours. In this study, we 
compared the activation, degranulation, and cytokine production of NK cells while 
co-culturing with C1R or C1R-MICA cells to assess the increment in NK cell 
responses upon NKG2D engagement. Considering TRAIL induction on NK cells is a 
potent regulation pathway involved in HBV-specific T cell deletion (Peppa et al., 
2013), we also evaluated TRAIL expression in the same co-culture setting.   
Our results revealed that encounters with NKG2D-L expressing cells could drive 
activation of NK cells from CHB patients. Notably, compared to other activation 
markers (CD25 or CD69), HLA-DR acted as a sensitive indicator to reflect NKG2D 
engagement responses in both total NK cells and, more strikingly, in the NKG2D 
positive fraction of NK cells (Figure 4.1A-C). The increase in activation of total NK 
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cells was consistent with the fact that a large proportion of NK cells express 
NKG2D. 
 
 
Figure 4.1 Evaluation of NK cell activation driven by NKG2D-L expressing 
cells. 
A Comparison summary of activation marker (CD69) changes of 
NK/NKG2D+NK cells in the setting of isolated NK cells co-cultured 
with C1R or C1R-MICA cells (CHB NK n=6; baseline levels of 
isolated NK cells were subtracted; analysed by Wilcoxon signed rank 
test). 
B Comparison summary of activation marker (CD25) changes of 
NK/NKG2D+NK cells in the setting of isolated NK cells co-cultured 
with C1R or C1R-MICA cells (CHB NK n=6; baseline levels of 
isolated NK cells were subtracted; analysed by Wilcoxon signed rank 
test). 
C Comparison summary of activation marker (HLA-DR) changes of 
NK/NKG2D+NK cells in the setting of isolated NK cells co-cultured 
with C1R or C1R-MICA cells (CHB NK n=10; baseline levels of 
isolated NK cells were subtracted; analysed by Wilcoxon signed rank 
test). 
 
Moreover, by comparing responses of isolated NK cells in co-culture with control 
C1R or C1R-MICA cells, our results also showed that NKG2D engagement could 
effectively activate degranulation (CD107a) and IFN-γ production in total NK cells 
and NKG2D+NK cells (Figure 4.2A and B). TRAIL ligand, by contrast, was not 
significantly induced by NKG2D engagement. (Figure 4.2C).  
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Figure 4.2 Evaluation of NK cell degranulation (CD107a), cytokine production 
(IFN-γ), and death ligand (TRAIL) expression induced by 
NKG2D-L expressing cells. 
A Comparison summary of degranulation (CD107a) changes of 
NK/NKG2D+NK cells in the setting of isolated NK cells co-cultured 
with C1R or C1R-MICA cells (CHB NK n=10; baseline levels of 
isolated NK cells were subtracted; analysed by Wilcoxon signed rank 
test). 
B Comparison summary of cytokine production (IFN-γ) changes of 
NK/NKG2D+NK cells in the setting of isolated NK cells co-cultured 
with C1R or C1R-MICA cells (CHB NK n=8; baseline levels of 
isolated NK cells were subtracted; analysed by Wilcoxon signed rank 
test). 
C Comparison summary of death ligand (TRAIL) expression changes of 
NK/NKG2D+NK cells in the setting of isolated NK cells co-cultured 
with C1R or C1R-MICA cells (CHB NK n=6; baseline levels of 
isolated NK cells were subtracted in the representative data; analysed 
by Wilcoxon signed rank test). 
 
Knowing that the NKG2D pathway as a stress surveillance system can trigger 
cytotoxicity towards NKG2D-L expressing targets (Eagle and Trowsdale, 2007; 
Shafi et al., 2011), we next examined whether NK cells from CHB patients would 
properly react to target cells with different NKG2D-L levels. Isolated NK cells from 
CHB patients were co-cultured with target cells at 1:1 ratio for 6 hours. Different 
MICA levels of target cells were manipulated by mixing C1R cells and C1R-MICA 
cells at different ratios. HLA-DR and CD107a staining were used for evaluating NK 
cell activation and degranulation activity, respectively. Live/Dead and Caspase 3 
were stained for determining target cell viability. 
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In this experiment, we found that the cell activation and cytotoxic degranulation of 
NKG2D+NK cells positively correlated with the MICA levels of target cells (Figure 
4.3A-C).  
 
 
Figure 4.3 Evaluation of NK cell activation (HLA-DR) and degranulation 
(CD107a) induced by target cells with different NKG2D-L levels. 
A Representative plots of NKG2D+NK cell activation (HLA-DR) and 
cytotoxicity (CD107a) in isolated NK cells (baseline) and in those 
co-cultured with target cells expressing different levels of MICA  
(MICA expression levels of target cells were manipulated by mixing 
C1R cells and C1R-MICA cells at different mix ratios). 
B Summary results of NKG2D+NK cell activation (HLA-DR) changes 
upon co-culture of isolated NK cells and target cells with different 
MICA expression levels (Baseline levels were subtracted).  
C Summary results of NKG2D+NK cell degranulation (CD107a) changes 
upon co-culture of isolated NK cells and target cells with different 
MICA expression levels (Baseline levels were subtracted).   
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Simultaneously, we also evaluated the corresponding target cell viability. In line with 
the increased activation and degranulation of NK cells, the induced target cell 
cytotoxicity (all apoptotic and dead cells) also positively correlated with their MICA 
levels (Figure 4.4A and B).  
 
Figure 4.4 Evaluation of target cell viability changes in the co-culture of 
isolated NK cells and target cells with different NKG2D-L levels.   
A Cell viability was evaluated by Live/Dead and Caspase 3 staining; 
lower left, lower right, upper right and upper left quadrant indicate 
viable, early apoptotic, late apoptotic, and necrotic populations, 
respectively. Representative plots of baseline viability in original target 
cells (C1R/C1R-MICA) and viability changes in different MICA 
expressing target cells co-cultured with NK cells.  
B Target cell cytotoxicity summary of panel A (Target cell cytotoxicity 
was the sum of all apoptotic and dead cells after subtraction of levels 
seen in baseline C1R/C1R-MICA cells).  
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target cells, which consequently leads to proportional apoptosis and death of target 
cells induced by the NKG2D pathway. 
 
4.3.2 Potent NKG2D-mediated cytotoxic degranulation of NK cells in chronic 
HBV infection 
In view of the noticeable increases of activation, degranulation, and cytokine 
production by NK cells following NKG2D engagement, we then compared responses 
in healthy controls and CHB patients. Isolated NK cells from healthy individuals or 
patients were co-cultured with either C1R cells or C1R-MICA cells at 1 to 1 ratio for 
6 hours. Enhanced responses from NK cells co-cultured with C1R-MCA cells 
compared to those co-cultured with C1R cells were regarded as NKG2D engagement 
effects. Additionally, background levels in isolated NK cells were evaluated to 
exclude unspecific or allogeneic reactions.   
MICA expressing target cells could significantly trigger the IFN-γ production and 
activation (HLA-DR) of NKG2D+NK cells in both healthy controls and CHB 
patients (Figure 4.5A-D). In parallel comparison of the increments, we found that the 
NKG2D-induced IFN-γ production and HLA-DR in patients were comparable to 
those in healthy controls (Figure 4.5A-D and data not shown). 
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Figure 4.5 Evaluation of NKG2D engagement induced cytokine production 
(IFN-γ) and activation (HLA-DR) changes in NK cells from healthy 
controls and CHB patients  
A Representative plots of NKG2D+NK cell IFN-γ production in isolated 
NK cells (baseline) and in those co-cultured with C1R or C1R-MICA 
cells. 
B Summary results of panel A (HC n=8; CHB n=8; baseline levels were 
subtracted; analysed by Wilcoxon signed rank test).  
C Representative plots of NKG2D+NK cell activation (HLA-DR) in 
isolated NK cells (baseline) and in those co-cultured with C1R or 
C1R-MICA cells. 
D Summary results of panel C (HC n=10; CHB n=10; baseline levels 
were subtracted; analysed by Wilcoxon signed rank test).  
 
In the same study arrangement, we also examined the degranulation activity 
(CD107a) of NK cells. Even though the MICA-expressing cells could effectively 
enhance CD107a in both healthy controls and CHB patients, the NKG2D 
engagement-induced degranulation of NK and NKG2D+NK cells was more 
pronounced in CHB patients (a mean 2.4-fold higher, Figure 4.6A-C).  
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Figure 4.6 Evaluation of NKG2D engagement induced degranulation (CD107a) 
changes in NK cells from healthy controls and CHB patients  
A Representative plots of NKG2D+NK cell degranulation (CD107a) in 
isolated NK cells (baseline) and in those co-cultured with C1R or 
C1R-MICA cells. 
B Summary results of panel A (HC n=10; CHB n=10; baseline levels 
were subtracted; analysed by Wilcoxon signed rank test).  
C Difference in enhanced levels of total NK/NKG2D+NK cell 
degranulation (CD107a) from NK cells co-cultured with C1R cells to 
those co-cultured with C1R-MICA cells (HC n=10; CHB n=10; 
analysed by Mann Whitney test).  
 
Next, we evaluated target cell viability in the same co-culture setting to compare the 
NKG2D-induced cytotoxicity by NK cells of healthy controls and CHB patients. In 
agreement with their potent degranulation activity upon NKG2D engagement, NK 
cells from CHB patients caused greater apoptosis and death of the MICA-expressing 
target cells (Figure 4.7A-C). Moreover, the induced apoptosis and death of 
C1R-MICA cells could be effectively reversed by NKG2D blockade via 
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anti-NKG2D mAb, indicating a direct effect from NKG2D/NKG2D-L interactions 
(Figure 4.7A and B). 
 
 
Figure 4.7 Evaluation of NKG2D engagement induced viability changes in 
target cells co-cultured with isolated NK cells from healthy controls 
or CHB patients.   
A Representative plots of target cell viability in original cell lines 
(C1R/C1R-MICA) and in those co-cultured with NK cells from healthy 
controls or CHB patients. Rescue of target cell apoptosis and death was 
conducted by adding NKG2D blocking mAb, using the IgG1 control 
isotype for comparison.  
B Target cell cytotoxicity summary of panel A (HC n=11; CHB n=11. 
Target cell cytotoxicity was the sum of all apoptotic and dead cells; 
baseline levels of C1R cells or C1R-MICA cells were subtracted; 
analysed by Friedman test). 
C Comparison summary of induced target cell cytotoxicity from C1R 
cells to C1R-MICA cells while co-cultured with NK cells (HC n=11; 
CHB n=11; analysed by Mann Whitney test). 
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In conclusion, our study demonstrates that cytotoxic immune responses by NK cells 
can be more effectively stimulated by NKG2D engagement in patients with CHB 
than healthy controls. Moreover, NK cells from CHB patients can cause potent 
cytotoxicity of target cells through the NKG2D pathway.  
 
4.3.3 NK cell activation responds to stressed T cells through NKG2D pathway 
in chronic HBV infection 
In CHB, the infected and inflamed liver milieu may alter NK cell phenotype and 
function. Down-regulation of the NKG2D receptor has been reported to occur in 
some situations of pathologic over-stimulation (Coudert et al., 2005; Groh et al., 
2002; Oppenheim et al., 2005). Considering that NKG2D expression may be affected 
by chronic HBV infection, we therefore evaluated the NKG2D levels on NK cells in 
PBMC and IHL from CHB patients. For comparison, we also used PBMC from 
healthy individuals and IHL of non-HBV infected controls, either from healthy tissue 
from liver metastasis resections or from transplant perfusates of deceased donor 
livers. Results showed both peripheral and intrahepatic NK cells from CHB patients 
maintained high levels of NKG2D similar to those from non-HBV infected controls 
(Figure 4.8A and B). Moreover, when compared to their peripheral counterparts, the 
levels of NKG2D were, surprisingly, even higher on intrahepatic NK cells of CHB 
patients (Figure 4.8A and B). 
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Figure 4.8 Evaluation of NKG2D expression of NK cells in chronic HBV 
infection.  
A Representative plots of ex vivo NKG2D expression on NK cells from 
paired blood and liver samples of a CHB patient. 
B Summary results of ex vivo NKG2D expression on NK cells of PBMC 
from healthy controls (n=23), paired PBMC and IHL from CHB 
patients (n=23), and IHL from non-HBV infected livers (n=14; filled 
circles (n=5) indicate intrahepatic lymphocytes isolated from healthy 
part of liver resection tissue; open circles (n=9) indicate intrahepatic 
lymphocytes isolated from transplant perfusates of deceased donor 
livers; analysed by Mann Whitney test and Wilcoxon signed rank test) 
 
Since our results showed that HLA-DR levels could sensitively reflect the activation 
responses of NK cells upon NKG2D engagement, we next evaluated the HLA-DR 
expression of NK cells directly ex vivo in PBMC and IHL from CHB patients and 
non-HBV infected controls. HLA-DR levels were significantly elevated on NK cells 
from CHB patients, especially the intrahepatic fraction, compared to those from 
PBMC or IHL of controls (Figure 4.9A and B). Upon further investigation of 
NKG2D+NK cell activation status, we also noticed that the HLA-DR levels were 
consistently upregulated on the NKG2D+ fraction of circulating and particularly 
intrahepatic NK cells from CHB patients, compared to those from non-HBV infected 
controls (Figure 4.9A and C).  
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Figure 4.9 Evaluation of activation (HLA-DR) of NK cells in chronic HBV 
infection.  
A Representative plots of ex vivo HLA-DR staining of total 
NK/NKG2D+NK cells from paired blood and liver samples of a CHB 
patient. 
B Summary results of ex vivo HLA-DR levels on NK cells of PBMC from 
healthy controls (n=12), paired PBMC and IHL from CHB patients 
(n=29), and IHL from non-HBV infected livers (n=17; filled circles 
(n=8) indicate intrahepatic lymphocytes isolated from healthy part of 
liver resection tissue; open circles (n=9) indicate intrahepatic 
lymphocytes isolated from transplant perfusates of deceased donor 
livers; analysed by Mann Whitney test and Wilcoxon signed rank test) 
C Summary results of ex vivo HLA-DR levels on NKG2D+NK cells of 
PBMC from healthy controls (n=9), paired PBMC and IHL from CHB 
patients (n=21), and IHL from non-HBV infected livers (n=14; filled 
circles (n=5) indicate intrahepatic lymphocytes isolated from healthy 
part of liver resection tissue; open circles (n=9) indicate intrahepatic 
lymphocytes isolated from transplant perfusates of deceased donor 
livers; analysed by Mann Whitney test and Wilcoxon signed rank test) 
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We next sought possible correlations between T cell expression of NKG2D-L and 
associated activation of NK cell responses within patients with CHB. In the extended 
analysis of our ex vivo study, we found that the proportion of activated (HLA-DR) 
NKG2D+NK cells positively correlates with periphery and liver MICA/B levels on 
CD4 T cells in CHB patients (Figure 4.10A and B). Since the majority of NK cells 
were NKG2D+, we also observed a similar positive, but weaker correlation between 
activation of total NK cells and MICA/B levels on CD4 T cells in the CHB liver. 
However, no such correlation was found with MICA/B on CD8 T cells (data not 
shown).   
 
 
Figure 4.10 Evaluation of NK cell activation and the associated correlation with 
T cell MICA/B expression in chronic HBV infection.  
A Correlation summary of ex vivo MICA/B expression on peripheral CD4 
T cells and HLA-DR levels of NKG2D+NK cells in CHB patients. 
(n=20; analysed by Spearman rank correlation test). 
B Correlation summary of ex vivo MICA/B expression on intrahepatic 
CD4 T cells and HLA-DR levels of NKG2D+NK cells in CHB patients 
(n=20; analysed by Spearman rank correlation test). 
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Results of these experiments led us to conclude that NK cells in CHB maintain high 
NKG2D levels and increased activation, particularly intrahepatic NK cells. The 
positive correlation between ex vivo NK cell activation and CD4 T cell NKG2D-L 
also implicates NK cell cross talk with T cells via the NKG2D pathway in CHB.   
 
4.3.4 Promotion of NKG2D dependent regulation during interferon therapy of 
CHB patients  
To date, interferon-alpha (IFN-α) with both immunomodulatory and anti-viral 
properties has been widely used as a first-line therapy for CHB (Lampertico et al., 
2015; Lucifora et al., 2014; Trepo et al., 2014). Nevertheless, undesirable side effects 
and frequent ALT flares (Nair and Perrillo, 2001; Perrillo, 2009; Saracco et al., 1994; 
ter Borg et al., 2008) limit the clinical usage of IFN-α therapy. Additionally, recent 
research has shown that IFN signalling drives oxidative stress-mediated liver injury 
in viral hepatitis (Bhattacharya et al., 2015), which is consistent with the transient 
increases in serum and intrahepatic IFN-α observed in CHB patients with hepatitis 
flares (Dunn et al., 2007; Fang et al., 1994; Wu et al., 2013). We therefore postulated 
that IFN-α therapy may impact NKG2D-dependent regulation in CHB.  
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To probe this possibility, we first compared the MICA/B expression on T cells of 
patients with CHB, both before and during pegylated interferon-α (PEG-IFN-α) 
therapy. By ex vivo staining of paired samples, we observed that T cell MICA/B 
expression increased when patients underwent PEG-IFN-α treatment (Figure 4.11A 
and B).  
 
 
Figure 4.11 Evaluation of effects of pegylated interferon-α (PEG-IFNα) therapy 
on T cell NKG2D-L induction.  
A Representative plots of ex vivo MICA/B expression on CD4 and CD8 T 
cells from a CHB patient before and during PEG-IFN-α treatment. 
B Comparison summary of panel A (n=8; gates set by control isotype 
staining; analysed by Wilcoxon signed rank test). 
 
Moreover, in a thorough longitudinal study of one patient, we found other NKG2D 
ligands, such as ULBP1, ULBP2/5/6 and ULBP3 also increased gradually during 
PEG-IFN-α therapy as well as MICA/B. (Figure 4.12A and B).  
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Figure 4.12 Longitudinal evaluation of pegylated interferon-α (PEG-IFNα) 
therapy on T cell NKG2D-L induction.  
A Longitudinal study of a CHB patient undergoing PEG-IFN-α therapy. 
Representative plots of ex vivo T cell MICA/B expression at 5 different 
intervals: 3 month pre-treatment, baseline pre-treatment, week three, 
week six, and week twelve of treatment. 
B Summary results of MICA/B, ULBP1, ULBP2/5/6, and ULBP3 
expression on T cells from the same CHB patient undergoing 
PEG-IFN-α therapy.   
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interferon-α at different concentrations for 4 hours. Consistent with the general 
consensus (Ahlenstiel et al., 2010; Vivier et al., 2008), we observed that IFN-α 
CD
8$
MICA/B$(gated$on$Live/CD3+)$
CD
4$
3M$before$Tx$$ Baseline$ PEGCIFNα$(3W)$ PEGCIFNα$(6W)$ PEGCIFNα$(12W)$
0.108$ 0.092$ 0.247$ 0.45$ 0.533$
0.136$ 0.11$ 0.224$ 0.454$ 0.784$
0"
0.04"
0.08"
0.12"
3M"before"
Treatment"
Baseline" PEG;IFNα"
(3W)"
PEG;IFNα"
(6W)"
PEG;IFNα"
(12W)"
CD4"ULBP2/5/6"
CD8"ULBP2/5/6"
0"
0.1"
0.2"
0.3"
3M"before"
Treatment"
Baseline" PEG9IFNα"
(3W)"
PEG9IFNα"
(6W)"
PEG9IFNα"
(12W)"
CD4"ULBP1"
CD8"ULBP1"
0"
0.3"
0.6"
0.9"
3M"before"
Treatment"
Baseline" PEG9IFNα"
(3W)"
PEG9IFNα"
(6W)"
PEG9IFNα"
(12W)"
CD4"ULBP3"
CD8"ULBP3"
0"
0.2"
0.4"
0.6"
0.8"
3M"before"
Treatment"
Baseline" PEG;IFNα"
(3W)"
PEG;IFNα"
(6W)"
PEG;IFNα"
(12W)"
CD4"MICA/B"
CD8"MICA/B"
(%MICA/B)* (%ULBP1)*
(%ULBP2/5/6)* (%ULBP3)*
A$
B$
  
 
117 
treatment could effectively enhance the cytotoxic degranulation of NK cells, 
especially the NKG2D positive fraction in a dose-dependent manner (Figure 4.13).  
 
 
Figure 4.13 Evaluation of interferon-α effects on NK cell degranulation activity.  
Purified NK cells isolated from a healthy donor were treated with 
interferon-α at different concentrations for 4 hours. Representative plots 
of NK cell (upper panels) and NKG2D+NK cell (lower panels) 
degranulation (CD107a) changes in untreated and interferon-α treated 
NK cells.  
 
Subsequently, we further investigated whether IFN-α treatment can augment NK cell 
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findings suggest that IFN-α pre-treatment could intensify NK cell killing towards 
target cells via the NKG2D pathway in both healthy controls and CHB patients.  
 
 
Figure 4.14 Evaluation of effects of interferon-α on NK cell killing towards 
NKG2D-L expressing cells.  
A Representative plots of target cell viability in C1R-MICA cells alone 
and in those co-cultured with untreated or IFN-α pretreated NK cells 
with/without NKG2D blockade.  
B Summary of NKG2D pathway related target cell cytotoxicity in 
untreated (UT) and IFN-α pretreated conditions (HC n=6; CHB n=6. 
NKG2D pathway related cytotoxicity was determined by viable cell 
(lower left quadrant) restoration upon NKG2D blockade in the 
co-culture of C1R-MICA cells with untreated or IFN-α pretreated NK 
cells; analysed by Wilcoxon signed rank test). 
 
To sum up, our results imply that through inducing NKG2D-L on T cells or boosting 
NK cell cytotoxicity, IFN-α signalling pathway is able to enhance NKG2D-mediated 
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4.4 Conclusions and Discussion   
It is known that NK cells participate in early cellular defence to virus infection 
(Vivier et al., 2008). However, accumulating evidence has also established their 
immune regulatory role (Crome et al., 2013; Lang et al., 2012; Waggoner et al., 
2010). In chronic viral infection, NK cells have been reported to mediate disease 
pathology and compromise anti-viral immunity (Rehermann, 2013; Rydyznski et al., 
2015; Schuster et al., 2014; Waggoner et al., 2012; Waggoner and Kumar, 2012). 
Indeed, NK cells have various dysfunctional traits in chronic HBV infection 
including defective non-cytolytic anti-viral function, and the capacity to impair 
antiviral T cell responses or mediate liver damage (Dunn et al., 2007; Ju et al., 2010; 
Peppa et al., 2010; Shi et al., 2012; Zhang et al., 2011b). Recently, our group has 
shown that NK cells can eliminate HBV-specific CD8 T cells via the TRAIL 
pathway as well as causing liver damage by killing HBV-infected hepatocytes 
(Peppa et al., 2013). Since NKG2D is a major activating receptor of NK cells with an 
important role in immune regulation and lymphoid stress surveillance (LSS) (Shafi et 
al., 2011; Strid et al., 2011), we chose to focus our study on the NKG2D axis. 
 
We first examined the reactions of NK cells following NKG2D engagement with a 
cell line transfected with MICA to allow a careful dose-response analysis. In our in 
vitro co-culture study, we observed that NKG2D-L expressing cells could effectively 
drive various effector responses of patient NK cells. In line with the general 
consensus that NKG2D is a highly sensitive stress sensor for NK cells (Shafi et al., 
2011), our study also demonstrated dose-dependent activation and cytotoxicity 
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towards NKG2D-L expressing cells. In the context of MICA- or ULBP2-transfected 
CHO cells, it has been shown that NKG2D-expressing NK cells can respond to 
relatively small changes in target cell NKG2D-L expression (Shafi et al., 2011). This 
was confirmed by our experiments titrating a MICA-expressing cell line and 
observing that as few as 10% MICA-expressing cells could activate 
NKG2D-dependent NK cell cytotoxicity. This frequency is likely to be fairly 
representative of the situation found within the liver sinusoids, where hepatic NK 
cells would first encounter HBV-specific T cells (Guidotti et al., 2015a; Peppa et al., 
2013), a large fraction of which expressed NKG2D-L. Additionally, NK cells from 
CHB patients presented greater degranulation activity upon NKG2D engagement 
compared to those from control subjects. The subsequent viability assays revealing 
greater NKG2D-induced cytotoxicity of target cells by patient NK cells supported 
this finding. This first demonstration that NK cells from CHB patients show 
enhanced responsiveness to NKG2D-L merits further investigation. As illustrated in 
recent human NK cell research, clusters of the inhibitory receptor KIR2DL1 on the 
surface of resting NK cells can influence signal thresholds and integration, thereby 
altering NKG2D responses of NK cells (Pageon et al., 2013). Moreover, previous 
studies also confirm that full effector function of naïve NK cells from healthy 
individuals can not be achieved merely by NKG2D stimulation alone, but required 
other cytokines or “priming” through other receptors (Bryceson et al., 2006b). 
Therefore, our results could not be accounted for simply by the levels of NKG2D 
expression, but instead suggest that NK cells from CHB patients may have different 
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thresholds of responsiveness to NKG2D engagement compared to naïve NK cells 
from healthy individuals. 
 
Secondly, we examined whether the HBV-infected and pathogenic liver milieu could 
interfere with NK cell phenotype and function (Maini and Peppa, 2013). Recent 
literature suggests that in some pathologic stimulations, over-exposure to soluble or 
membrane-bound NKG2D ligands may cause NKG2D down-regulation (Coudert et 
al., 2005; Groh et al., 2002; Oppenheim et al., 2005). However, in line with previous 
HBV research (Boni et al., 2015; Oliviero et al., 2009; Zhang et al., 2011b; Zhao et 
al., 2012), our study revealed NK cells from CHB patients maintained high levels of 
NKG2D and were highly activated compared to those from healthy controls. By 
extensive analysis of paired blood and liver samples, we showed for the first time 
that, paradoxically, NKG2D is even more highly expressed on intrahepatic than 
peripheral NK cells. Similarly, high levels of NKG2D were noted in uninfected 
livers, indicating that the hepatic niche supports NKG2D expression, although there 
was considerable unexplained inter-donor variability. Further studies in our group 
will investigate the mechanisms favouring NKG2D expression in the liver. Possible 
candidates are cytokines such as IL-15 and IFN-α which can accumulate within the 
HBV-infected liver (Fang et al., 1994; Wu et al., 2013; Zhang et al., 2011b) and are 
known to enhance effector function and NKG2D expression of NK cells (Burgess et 
al., 2008; Dann et al., 2005; Konjevic et al., 2010; Nielsen et al., 2012; Tang et al., 
2013). Collectively, our results reveal that NK cells maintain high NKG2D 
expression and NKG2D-mediated regulation is fostered in CHB.  
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NK cells are known to be more activated and cytotoxic in the HBV-infected liver but 
factors driving this have not been previously identified (Dunn et al., 2007; Zhang et 
al., 2011b). Here we have identified a selective increase in activation of the 
NKG2D+ fraction of intrahepatic NK cells, pointing to a key role for this major 
activating receptor. We go on to demonstrate that NKG2D-expressing NK cells have 
an exaggerated activation of cytotoxicity in response to NKG2D-L and to identify a 
source of NKG2D-L expressing T cells that would be expected to come into close 
contact with NK cells within the hepatic vasculature. We provide ex vivo evidence 
suggesting that induction of NKG2D-L on liver-infiltrating CD4 T cells is a factor 
driving the activation of intrahepatic NK cells in the HBV-infected liver. 
 
Interferon-alpha (IFN-α) is a first-line regimen and the only currently available 
treatment that can target HBV cccDNA (Lampertico et al., 2015; Lucifora et al., 
2014). However, the undesirable side effects and frequent ALT flares (Nair and 
Perrillo, 2001; Perrillo, 2009; Saracco et al., 1994; ter Borg et al., 2008) are 
legitimate concerns in clinical usage. Indeed, recent research has pointed out that 
type I IFN signalling activation can drive oxidative liver damage in murine viral 
hepatitis (Bhattacharya et al., 2015). In accordance with our previous study 
suggesting oxidative stress in CHB could be a factor for NKG2D-L induction, 
patients undergoing PEG-IFN-α therapy exhibited elevated levels of NKG2D-L on T 
cells. Moreover, the type I IFN signalling pathway has been shown to interfere with 
T cell immunity and consequently contribute to persistent viral infection (Osokine et 
al., 2014; Teijaro et al., 2013; Wilson et al., 2013). Our group has previously shown 
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that HBV IFN-α therapy has divergent effects, which leads to significant loss of T 
cells, but conversely boosts NK cell effector activity (Micco et al., 2013; Thimme 
and Dandri, 2013). Accordingly, besides the augmentation of NK cell activation, 
proliferation, and cytokine production, many studies documented both endogenous 
and therapeutic IFN-α can induce TRAIL upregulation on NK cells which could 
promote their killing of hepatocytes and T cells (Dunn et al., 2007; Edlich et al., 
2012; Micco et al., 2013; Stegmann et al., 2010; Thimme and Dandri, 2013). 
Corresponding to our findings showing IFN-α could drive cytotoxic degranulation of 
NK cells, we also observed IFN-α could amplify NKG2D-mediated NK cell killing 
of target cells. Previous work has similarly shown that upregulation of MICA/B on 
IFN-α stimulated cells (Jinushi et al., 2003a; Jinushi et al., 2003b; Zhang et al., 2008) 
and IFN-α-driven enhancement of both NKG2D expression and NKG2D-mediated 
degranulation of NK cells (Burgess et al., 2008; Konjevic et al., 2010; Nielsen et al., 
2012; Zhang et al., 2005). Collectively, these results, together with the Lang et al. 
murine LCMV study (Lang et al., 2012), all imply that IFN-α could play a key role 
in NKG2D-related NK cell regulation. Thus, to enhance anti-HBV responses and 
minimize unwanted inhibitory immunomodulation, manipulation of the NKG2D 
pathway may need to be considered in combination with IFN-α therapy.   
 
To sum up, our research implies a paradoxical triangular relationship between HBV 
infection, innate immunity, and adaptive immunity. The inflammatory HBV-infected 
liver milieu with aberrant stress could lead to stress ligand upregulation on T cells, 
such as the NKG2D-L observed in our study. Upregulated NKG2D-L could drive 
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NK cell activation and cytotoxicity induction and subsequently contribute to NK 
cell-mediated T cell deletion via the NKG2D pathway. This pathogenic cellular 
communication could compromise anti-viral immunity and further facilitate 
persistent HBV infection as well as long-term liver inflammation. Therefore, to 
optimize hepatitis B treatment, attempts to diminish HBV replication and minimize 
hepatic oxidative stress should be prioritized, thereby breaking the vicious 
destructive cycle (Figure 4.15). 
 
 
Figure 4.15 Depiction of the paradoxical relationship between HBV infection, 
innate immunity, and adaptive immunity in the NKG2D axis.  
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Chapter 5 Future Outlook and Potential Directions   
Evaluating other CD4 T cell subsets in CHB 
In our study, we have shown NKG2D-L preferentially enriched on CD4 T cells in 
CHB patients. In particular, activated and HBV-specific CD4 T cells expressed 
higher levels of NKG2D-L compared to other T cell populations. Comprising many 
different subsets, CD4 T cells have diverse immunological functions in viral 
infection. For example, regulatory CD4 T cells (Treg) possessing 
immunosuppressive properties have been implicated in suppression of anti-viral 
immunity and liver inflammation in HBV infection (Manigold and Racanelli, 2007; 
Xu et al., 2006). In the extended analysis of our ex vivo study, we observed that 
CD25hiCD127loFoxp3+CD4 Treg cells expressed slightly higher MICA/B than the 
general CD4 population (Figure 5.1A and B). However, the immunological 
implications of this observation still remain to be determined.  
Moreover, in murine virus research, follicular helper CD4 T cells (TFH) have been 
documented to be suppressed by NK cells, which leads to a weakened germinal 
centre response and compromised humoral immunity (Rydyznski et al., 2015).  
Therefore, further investigation of CD4 T cell sub-populations in relation to the 
NKG2D axis or NK cell regulation may improve our understanding of immune 
defects in HBV chronicity.    
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Figure 5.1 Evaluation of NKG2D-L expression on CD4 Treg cells in CHB 
patients. 
A CD4 Treg cells were identified by CD25hiCD127lo and Foxp3+ staining.  
Representative plots of ex vivo MICA/B expression on CD4 T cells and 
CD4 Treg cells from CHB patients. 
B Summary results of panel A (n=11; analyzed by Wilcoxon signed rank 
test). 
 
Evaluating other pathways of NK cell regulation in CHB 
Our results illustrated that NK cells have immune regulatory effects via the NKG2D 
pathway in chronic HBV infection. However, other pathways, such as DNAM-1 can 
also contribute to NK cell killing of T cells (Ardolino et al., 2011; Zingoni et al., 
2012). Indeed, DNAM-1 and NKG2D are two mechanisms sharing many similarities 
in NK cell-mediated T cell regulation, particularly since ligands for both of these 
activating receptors can be induced on T cells by oxidative stress (OS) (Ardolino et 
al., 2011; Rabinovich et al., 2000; Zingoni et al., 2012). Furthermore, recent research 
also demonstrated that OS-induced DNAM-1 ligand expression is related to the 
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DNA damage responses (DDR) (Ardolino et al., 2011). Thus, evaluation of 
DNAM-1 pathway involvement and evidence of a T cell DDR (such as γ-H2AX or 
p38 phosphorylation assessment) in CHB patients would be interesting. From a 
therapeutic standpoint, using reactive oxygen species scavengers (such as 
N-acetylcysteine) or DDR inhibitors (such as ATM/ATR kinase inhibitors) to 
diminish NK cell regulation could be a promising approach.  
 
Evaluating the T/NK cell interplay by longitudinal follow-up and murine models  
HBV is a non-cytopathic, hepatotropic virus that persistently infects the majority of 
hepatocytes in chronic carriers (Seeger and Mason, 2000; Yoo et al., 1987). Within 
an HBV-infected patient, the host immunity usually stays in a precarious balance 
between virus control and tissue damage (Guidotti and Chisari, 2006; Guidotti et al., 
2015b). Recent data suggest that through the course of HBV infection, NK cells and 
T cells can respond conversely, presenting an inverse correlation (Boni et al., 2015; 
Grimm et al., 2013; Isogawa and Tanaka, 2015; Peppa et al., 2013). As such, in naïve 
CHB patients, NK cells with “inflammatory” phenotypes having regulatory activity 
show increased activation, proliferation and TRAIL expression (Boni et al., 2015; 
Peppa et al., 2013; Zhang et al., 2011b). In contrast, virus-suppressed and 
ALT-normalized patients with NK cells showing “resting” profiles have reciprocal 
improvement of the HBV-specific T cell immunity following nucleos(t)ide analogue 
treatment (Boni et al., 2012; Boni et al., 2015; Thimme and Dandri, 2013). In 
agreement with evidence indicating the pathogenic regulation of NK cells positively 
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corresponds with the hepatitis severity in CHB patients (Dunn et al., 2007; Zhang et 
al., 2011b), research also demonstrates the preserved T cell function in CHB patients 
with no/minimal liver inflammation in the immune-tolerant phase (Kennedy et al., 
2012). Therefore, continuing our NKG2D research and further investigating T/NK 
cell interplay by longitudinal evaluation of patients with hepatitis flares or those 
undergoing anti-HBV treatment may provide substantial information for re-directing 
pathogenic immunomodulation towards favorable virus elimination.   
Alternatively, using in vivo murine models (such as transgenic knockout or in vivo 
blockade) may offer better opportunities to promptly reflect actual cellular 
interactions, since in vitro functional assessments are difficult to reproduce real 
biological conditions for NK cells and T cells. However, the distinctly different 
NKG2D systems across species, and the fact that HBV is unable to replicate in 
mouse hepatocytes, make establishing an ideal animal/infection model for in vivo 
studies in this field an ongoing challenge (Allweiss and Dandri, 2016). 
 
Evaluating other correlations between liver pathology and host immunity  
In view of the fact that NK cells account for the largest fraction (30~40%) of 
intrahepatic lymphocytes, they have a key role in immunity and pathology 
modulation (Doherty et al., 1999; Dunn et al., 2007; Maini and Peppa, 2013). Our 
study has illustrated that the prominent NKG2D-L upregulation on T cells in the 
HBV-infected liver can contribute to the activation and cytotoxicity induction of NK 
cells to subsequently constrain adaptive immunity. However, while probing other 
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possible connections between the liver histological activity index (HAI) with 
NKG2D-L of T cells or activation of NK cells, we did not observe significant 
correlations in our patient cohort. This may be partly due to the lack of diversity in 
our subjects with a narrow homogeneous pattern of clinical parameters (ALT max 
150; ISHAK fibrosis score 1~3; HAI 3~7).  
Actually, this is a common issue in human liver research, since patients with greater 
severity of cirrhosis or liver function impairment are likely excluded from the 
invasive procedure of liver biopsy (Duygu et al., 2012). Moreover, the accessibility 
of human tissue also limits studies for other intrahepatic cell types (Kupffer cells, 
hepatocytes, or stellate cells) in the context of various liver diseases, such as HCV 
hepatitis, nonalcoholic steatohepatitis, or autoimmune hepatitis. Therefore, further 
research and expanding our data are essential and may reveal noteworthy links 
between liver pathology and host immunity in the future. 
 
Evaluating NKG2D regulation of NK cells in CHB  
As illustrated in our co-culture experiments, NKG2D expression on NK cells could 
be down-regulated by NKG2D-L expressing target cells (membrane-bound 
NKG2D-L) (Figure 5.2A and B). However, we did not witness this phenomenon in 
our ex vivo study. On the contrary, NK cells from CHB patients were highly 
activated and maintained high levels of NKG2D. One possible explanation could be 
that the cytokine milieu of the HBV-infected liver, such as the local expression of 
IL-15, can enhance NKG2D expression and also activate NK cells (Dann et al., 2005; 
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Tang et al., 2013; Zhang et al., 2011b). Alternatively, if soluble NKG2D-L 
(sNKG2D-L) are shed in CHB, they may participate in the maintenance of NKG2D 
expression. Although engagement by sNKG2D-L has been suggested to cause 
down-regulation of NKG2D on NK cells in most human research (Holdenrieder et al., 
2006a; Raffaghello et al., 2004; Raulet et al., 2013; Salih et al., 2002), one recent 
murine study showed sNKG2D-L from tumor-associated cells could maintain 
NKG2D expression and boost NK cell activation to promote tumor rejection (Deng 
et al., 2015). Certainly, the NKG2D system in different species involving different 
receptors, ligand affinities and activating capabilities may cause opposing results in 
mice and humans. However, further investigation of the impact on NKG2D of 
various cytokines and sNKG2D-L from serum or hepatocytes is necessary and 
currently being carried out by our group. 
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Figure 5.2 Evaluation of NK cell NKG2D down-regulation by cell-bound 
NKG2D-L.  
A Isolated NK cells from CHB patients were co-cultured with target cells 
at 1:1 ratio for 6 hours. Different MICA levels of target cells were 
manipulated by mixing C1R cells and C1R-MICA cells at different mix 
ratios. Representative plots of NKG2D on isolated NK cells (baseline) 
and on NK cells co-cultured with target cells. 
B Summary of panel A (n=6; analyzed by Friedman test). 
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NKG2D-driven cytotoxicity of NK cells may have important homeostatic 
significance. As we know, multiple factors triggering NKG2D-L upregulation, such 
as repeated liver destruction and regeneration, genotoxin and DNA damage, 
persistent antigenic stimulation, and aberrant oxidative stress, can all exist in the 
HBV-infected liver (Cougot et al., 2005; Guerrieri et al., 2013; Raulet et al., 2013). 
These detrimental forces can ubiquitously and continuously affect different kinds of 
cells and promote carcinogenesis and pathogenesis (Cougot et al., 2005; Guerrieri et 
al., 2013). Thus, to restore homeostasis in such high oncogenetic and pathogenic 
situations, NK cells need to be equipped with competent NKG2D effector function 
(Oliviero et al., 2009). Moreover, since tumour transformation and cell stress 
responses share the same features of NKG2D-L induction, the NKG2D pathway 
must be crucial for both “cancerous” and “stressed” cell surveillance. Therefore, 
further assessment of the NKG2D axis in the settings of HBV-related liver cancer or 
cirrhosis is necessary.  
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List of Achievements and Experiments Conducted      
1. Evaluation of NKG2D ligand expression on intrahepatic T cells from 
healthy controls and CHB patients.  
2. Evaluation of proliferation status (Ki67) of MICA/B+T cells from healthy 
controls and CHB patients.  
3. Phenotype analysis of peripheral and intrahepatic MICA/B+T cells from 
CHB patients.  
4. Evaluation of NKG2D ligand expression on CD4 Treg cells from CHB 
patients. 
5. Evaluation of NKG2D ligand expression on peripheral and intrahepatic 
HLA-DR+T cells from CHB patients. 
6. Evaluation of NKG2D ligand expression on peripheral and intrahepatic 
HBV-specific (IFN-γ+) T cells from CHB patients 
7. Assessment of NKG2D ligand expression on peripheral HBV and 
CMV-specific (dextramer+) CD8 T cells from CHB patients. 
8. Preliminary assessment of NKG2D ligand expression on intrahepatic HBV 
and CMV-specific (dextramer+) CD8 T cells from CHB patients  
(inconclusive results and insufficient data, n=2; poor quality of intrahepatic 
dextramer staining).  
9. Preliminary assessment of T cell MICA/B induction by using IFN-α, TNF-α, 
IL-2, IL-10, IL-15, IL-17, EGF, αCD3, αCD28, PMA, ionomycin, 
L-arginine depleted medium, hypoxic incubation, HBcAg, HBsAg, and 
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CHB patient serum as well as ER stress inducer thapsigargin (all without 
positive results).  
10. Evaluation of NKG2D ligand induction on purified CD4 T cells upon TCR 
signalling or oxidative stress (H2O2) stimulation. 
11. Assessment of time-course and dose-response of NKG2D ligand induction 
upon oxidative stress (H2O2) stimulation of purified CD4 T cells. 
12. Comparison of NKG2D ligand induction upon oxidative stress (H2O2) 
stimulation in purified CD4 T cells and in whole PBMC. 
13. Evaluation of upregulation of death receptor (Fas) and exhaustion marker 
(PD-1) on NKG2D-L expressing CD4 T cells upon oxidative stress (H2O2) 
stimulation. 
14. Preliminary phosflow assessment of T cell γ-H2AX phosphorylation from 
CHB patients (technical problems: the recommended methanol 
permeabilization buffer influenced the surface staining). 
15. Evaluation of NKG2D-L responses upon H2O2 stimulation with/without 
ATM kinase inhibitor (preliminary results revealed ATM kinase inhibitor 
was unable to prevent OS-mediated NKG2D-L induction; n=6).  
16. Evaluation of the impact of NKG2D pathway and NK cells on activated T 
cells in patients with CHB.  
17. Evaluation of the impact of NKG2D pathway and NK cells on 
HBV-specific (IFN-γ+) T cells in patients with CHB.  
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18. Comparison of the impact of NKG2D pathway and NK cells on HBV and 
CMV-specific (IFN-γ+) T cells in patients with CHB (inconclusive results 
and insufficient data, n=2). 
19. Evaluation of the impact of NKG2D pathway on intrahepatic HBV-specific 
T cells in patients with CHB. 
20. Preliminary assessment of HBV-specific (IFN-γ+) T cell restoration upon 
NKG2D blockade together with TRAIL blockade (inconclusive results and 
insufficient data, n=1; poor viability was noted in cells with double pathway 
blockade).  
21. Preliminary assessment of HBV-specific (IFN-γ+) T cell restoration upon 
MICA blockade (inconclusive results and insufficient data, n=1; poor 
viability was noted in cells treated with MICA blocking mAb).  
22. Evaluation of NK cell activation (HLA-DR, CD38, CD69, CD25) driven by 
NKG2D-L expressing cells. 
23. Evaluation of NK cell degranulation (CD107a), cytokine production (IFN-γ), 
and death ligand (TRAIL) expression induced by NKG2D-L expressing 
cells. 
24. Evaluation of NK cell activation (HLA-DR) and degranulation (CD107a) 
induced by target cells with different NKG2D-L levels. 
25. Evaluation of target cell viability changes in the co-culture of isolated NK 
cells and target cells with different NKG2D-L levels.   
  
 
172 
26. Evaluation of NKG2D engagement induced cytokine production (IFN-γ) 
and activation (HLA-DR) changes in NK cells from healthy controls and 
CHB patients  
27. Evaluation of NKG2D engagement induced degranulation (CD107a) 
changes in NK cells from healthy controls and CHB patients  
28. Evaluation of NKG2D engagement induced viability changes in target cells 
co-cultured with isolated NK cells from healthy controls or CHB patients.   
29. Assessment of the activation status (HLA-DR) and NKG2D expression of 
peripheral and intrahepatic NK cells from CHB patients and non-HBV 
infected controls.  
30. Evaluation of NK cell activation and the associated correlation with T cell 
MICA/B expression in chronic HBV infection.  
31. Evaluation of effects of pegylated interferon-α (PEG-IFNα) therapy on T 
cell NKG2D-L induction.  
32. Preliminary flocytometry assessment of 2’-5’-oligoadenylate synthetase 1 of 
T cells from patients with CHB (technical problems: the recommended 
methanol permeabilization buffer influenced the surface staining). 
33. Evaluation of IFN-α effects on NK cell degranulation activity.  
34. Evaluation of effects of IFN-α on NK cell killing towards NKG2D-L 
expressing cells.  
35. Evaluation of NK cell NKG2D down-regulation by cell-bound NKG2D-L 
(C1R-MICA cells).  
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36. Preliminary evaluation of NK cell NKG2D changes upon soluble 
NKG2D-L (sULBP1) and IL-15 stimulation (inconclusive results and 
insufficient data, n=1).  
 
